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8. Secondary hypertension
8.1. Introduction
Secondary hypertension is present in 5–10% of all 
hypertensive patients. Appropriate investigations 
followed by therapy directed at the cause of sec-
ondary hypertension may lead to elimination of the 
underlying cause, resulting in improved control or 
normalization of BP values with cardiovascular risk 
reduction.
Clues to the presence of secondary hypertension 
include:
• severe BP elevation (including paroxysmal hyper-
tension and hypertensive crisis);
• rapidly progressing development of hypertension 
or worsening of BP control;
• resistant hypertension;
• development of malignant hypertension;
• poor response to antihypertensive drugs;
• presence of target organ damage that is dispropor-
tionate to the duration or severity of hypertension.
Suggestive signs and symptoms and diagnostic 
procedures to investigate for specific forms of second-
ary hypertension are summarized in Table XXXVII.
8.2. Obstructive sleep apnoea
8.2.1. Prevalence
Obstructive sleep apnoea (OSA) is present in a rela-
tively large proportion of hypertensive patients, par-
ticularly among those with resistant hypertension 
(about 80%). Studies indicate that moderate to se-
vere OSA that requires appropriate therapeutic man-
agement may be present in as many as 40–50% of 
patients with resistant hypertension. Of note, OSA 
is also associated with a 70% relative increase in the 
cardiovascular morbidity and mortality risk.
Due to frequent coexistence, common pathoge-
netic mechanisms with hypertension, and a limited 
effect of specific OSA treatment on BP values, some 
European experts have postulated to consider it 
a concomitant condition and not a secondary form 
of hypertension. However, American guidelines 
(JNC7) have listed OSA as an important and revers-
ible cause of secondary hypertension.
8.2.2. History, physical examination, and routine 
and additional laboratory test abnormalities
The most common symptoms of OSA are habitual 
snoring, episodes of apnoea, and excessive daytime 
somnolence. Other manifestations of OSA in-
clude the following nocturnal symptoms: nycturia, 
increased motor activity and sweating during the 
night, awakenings, dyspnoea and/or choking during 
sleep, difficulties with falling asleep, insomnia, pal-
pitations, mouth and throat dryness, and symptoms 
of gastroesophageal reflux. In addition to excessive 
daytime somnolence, other symptoms during the 
day include morning tiredness, morning headaches, 
impaired memory and concentration, decreased libi-
do and impotence, psychoemotional problems, and 
an increased rate of traffic and workplace accidents. 
Studies also indicate that in some hypertensive pa-
tients, daytime symptoms of even severe OSA may 
be modest.
Obesity is the most common finding on physical 
examination, in particular abdominal obesity. The 
corrected neck circumference above 48 cm (mea-
sured neck circumference in centimetres plus 4 cm in 
hypertensives plus 3 cm if habitual snoring, and plus 
3 cm if nocturnal choking/dyspnoea) is associated 
with a significantly increased risk of OSA.
Major underlying causes may include anatomical 
abnormalities of the upper airways, such as tongue 
hypertrophy, elongation of the soft palate, tonsil hy-
pertrophy, and impaired nasal patency. Less frequent 
abnormalities include an abnormal anatomy of the 
splanchnocranium, for example mandibular hypo-
plasia and/or retraction.
Most commonly, OSA coexists with metabolic 
syndrome and thus abnormal glucose and lipid me-
tabolism is often indicated by basic laboratory tests 
in these patients.
In patients with OSA, ABPM may reveal a re-
duced nocturnal BP fall, non-dipping BP pattern, 
or even BP elevation during the night. The presence 
of OSA may also be indicated by increased morning 
BP values as detected by HBPM. Holter monitoring 
in patients with OSA may show intermittent periods 
of brady- and tachycardia. Echocardiography may 
show left ventricular hypertrophy (usually of the 
concentric pattern), left atrial enlargement, diastolic 
dysfunction, and other abnormalities.
8.2.3. Investigations
Investigations for OSA should be considered in 
hypertensive patients with:
• clinical symptoms suggesting OSA;
• resistant hypertension;
• abdominal obesity and metabolic disturbances 
(particularly diabetes);
• concomitant coronary artery disease;
• a history of stroke/TIA;
• non-dipping BP pattern;
• nocturnal arrhythmia and/or conduction distur-
bances.
Available questionnaires, such as the Epworth 
Sleepiness Scale and the Berlin Questionnaire, lack 
specificity to allow excluding OSA. However, they 
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may be helpful in identifying patients at an increased 
risk of OSA and should be included in the basic 
evaluation of a hypertensive patient.
Investigations for OSA include 4 types of diagnos-
tic devices and systems:
I. Complete polysomnography performed in a sleep 
laboratory.
II. Portable (unsupervised) polysomnography, re-
cording a minimum of 7 channels, including all 
that are necessary to evaluate the sleep structure 
and the breathing pattern.
III. Respiratory polygraphy, or a limited recording of 
at 4 least parameters, including respiratory move-
ments of the chest and abdomen, air flow through 
the upper airway, and arterial oxyhaemoglobin sat-
uration, without evaluation of the sleep structure.
IV. Recording of maximum 2 parameters, e.g., noc-
turnal pulse oximetry.
Use of different diagnostic devices and the diag-
nostic algorithm in cases of suspected OSA are sum-
marized in Figure 9.
8.2.4. Diagnostic criteria1 
For the diagnosis of OSA, the criteria A, B, and D, 
or C and D must be met.
A. At least one of the following:
• inadvertent falling asleep, excessive daytime som-
nolence, ineffective sleep, tiredness, or insomnia;
• awakenings with the feeling of breathing cessa-
tion, dyspnoea or choking;
• habitual snoring or episodes of apnoea noted by 
the partner of the patient.
B. Polysomnography findings:
• at least 5 disordered breathing events per hour of 
sleep (AHI ≥ 5);
• respiratory muscle activity noted during these 
episodes;
C. Polysomnography findings:
• at least 15 disordered breathing events per hour 
of sleep (AHI ≥ 15);
• respiratory muscle activity noted during these 
episodes;
D. The above findings are not related to other sleep 
disturbances, conditions (including neurological dis-
ease), or use of medications or other substances.
Classification of the severity of OSA:
• mild OSA (AHI ≥ 5 and ≤ 15);
• moderate OSA (AHI > 15 and ≤ 30);
• severe OSA (AHI > 30).
1Modified American Academy of Sleep Medicine (AASM) criteria. In the original document, the diagnosis 
is based on the respiratory disturbance index (RDI) which includes apnoeas, hypopnoeas, and respiratory 
effort related arousals (RERA). However, many authors use the apnoea-hypopnoea index (AHI) for the 
diagnosis and evaluation of the severity of OSA, particularly in studies on the prevalence of OSA among 
hypertensives. Clinically, the difference between RDI and AHI is usually not significant, and reliable eva-
luation of RERA episodes requires oesophageal pressure measurement during sleep, and the latter is not 
routinely recorded during polysomnography. If RERA episodes cannot be evaluated, than AHI = RDITa
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8.2.5. Management of obstructive sleep apnoea
The management of OSA includes the following:
• body weight reduction (in all patients);
• avoidance of a supine position during sleep (in 
patients with confirmed positional OSA) or sleep-
ing in a semi-sitting position (in patients with 
mild or moderate OSA without severe obesity);
• avoidance of alcohol intake (in all patients);
• smoking cessation (in all patients);
• avoidance of sedative-hypnotics and narcotic an-
algesics (in all patients);
• mandibular advancement devices (simple snor-
ing and mild OSA not responsive to behavioural 
treatment);
• continuous positive airway pressure (CPAP) 
therapy [all patients with AHI > 30; patients 
with AHI > 15 and excessive daytime somno-
lence (Epworth Sleepiness Scale score > 10) or 
cardiovascular disease; in some cases CPAP may 
be considered in patients with AHI 5–15];
• surgical upper airway procedures (indications set 
on an individual basis, particularly in non-obese 
patients).
Studies indicate that regular use of CPAP for an 
appropriately long period of time during the night 
may be associated with BP lowering, particularly in 
patients with resistant hypertension, and may have 
a beneficial effect on the reduction of cardiovascular 
event risk.
8.2.6. Treatment of hypertension in patients 
with obstructive sleep apnoea
Limited data are available to develop recommenda-
tions regarding antihypertensive therapy in patients 
with OSA. Some evidence suggests benefits of diuret-
ics, in particular aldosterone antagonists, in terms 
of not only improvement of BP control but also 
reduction of the severity of OSA. However, these 
studies were performed in small groups of patients 
and further studies are required. Further research is 
also necessary to determine potential benefits of renal 
denervation in these patients.
8.2.7. Care for patients with hypertension 
and concomitant obstructive sleep apnoea
The following issues should be evaluated during each 
visit related to the treatment of hypertension:
• in patients with previously undiagnosed OSA:
 — symptoms suggestive for, and the risk of OSA,
 — indications for investigations to diagnose OSA;
• in patients with established OSA without previ-
ous indications for CPAP therapy:
 — compliance regarding behavioural therapy for OSA,
 — indications for reassessment of the severity of OSA;
• in patients with established OSA and indications 
for CPAP therapy:
 — compliance regarding behavioural therapy for OSA,
 — compliance regarding CPAP therapy, and factors 
associated with noncompliance,
Figure 9. Diagnostic algorithm for obstructive sleep apnoea. AASM — American Academy of Sleep Medicine; BP — blood pressure; 
OSA — obstructive sleep apnoea; TIA — transient ischemic attack
Indications for investigating OSA
Nocturnal study using a type IV device
High likelihood of OSA
Nocturnal study using a type I, II, or III device
Diagnosis of OSA based on the AASM criteria
Symptoms of OSA
 Resistant hypertension
 Abdominal obesity and metabolic disturbances (particularly diabetes)
 Coronary artery disease
 Previous stroke/TIA
 Non-dipping BP pattern
 Arrhythmia/conduction disturbances during sleep
 Nycturia > 2 times per night
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 — frequency and duration of CPAP use during the 
night (based on data retrieved from the device 
memory).
8.3. Atherosclerotic renal artery stenosis
8.3.1. Definition
Hypertension due to renal artery stenosis, also known 
as renovascular hypertension, is a secondary form of 
hypertension caused by excessive renin production in 
the ischemic kidney. Significant renal artery stenosis 
does not only produce hypertension but also impairs 
excretory, endocrine, and homeostatic renal function 
and results in ischemic nephropathy. In some patients, 
renal artery stenosis is a cause of end-stage renal dis-
ease and the need for renal replacement therapy. Most 
commonly, renal artery stenosis is of atherosclerotic 
origin. The second most common cause of renal artery 
stenosis is fibromuscular dysplasia, which is discussed 
in a separate section of the present document.
8.3.2. Clinical presentation of atherosclerotic 
renal artery stenosis
Investigations for atherosclerotic renal artery stenosis 
should be considered particularly in patients with:
• hypertension that is:
 — severe,
 — resistant to treatment,
 — malignant (accelerated);
• episodes of unexplained flash pulmonary oedema 
(Pickering syndrome) and/or unexplained con-
gestive heart failure;
• unexplained renal failure (including patients in 
whom renal replacement therapy is initiated);
• new-onset azotaemia or worsening of renal func-
tion following administration of a RAS inhibitor;
• hypokalaemia, particularly in patients treated 
with diuretics;
• an abdominal bruit;
• difference in kidney length > 1.5 cm or a small 
kidney of unknown cause.
Atherosclerotic renal artery stenosis should also be 
suspected in hypertensive patients with atherosclerosis 
in other vascular beds, including coronary arteries. The 
rates of atherosclerotic renal artery stenosis correlate with 
the severity of atherosclerosis in other vascular beds.
Symptoms and signs and laboratory test findings 
suggestive of atherosclerotic renal artery stenosis are 
summarized in Table XXXVII.
8.3.3. Screening and confirmatory diagnostic 
methods for atherosclerotic renal artery stenosis
8.3.3.1. Doppler renal ultrasonography
Doppler renal ultrasonography is recommended as 
the first-line noninvasive diagnostic test in patients 
with suspected renal artery stenosis. It allows evalua-
tion of the extra- and intrarenal arteries and localiza-
tion of the stenosis. Assessment of the resistive index 
(RI) may be helpful for evaluating significance of 
a stenosis (difference versus the contralateral kidney 
≥ 0.05) or predicting procedural outcomes.
In case of normal Doppler renal ultrasonogra-
phy findings in patients with a significant clinical 
suspicion of renal artery stenosis, computed tomog-
raphy angiography (CTA) or magnetic resonance 
angiography (MRA) of the renal arteries should be 
performed.
Doppler renal ultrasonography allows long-term 
follow-up of patients after correction of renal artery 
stenosis (to exclude recurrent stenosis) and evalu-
ation of disease progression in medically treated 
patients. Follow-up examinations in revascularized 
patients should be performed immediately after the 
revascularization procedure and 6–12 months after-
wards. Follow-up examinations to evaluate progres-
sion of borderline lesions treated medically should be 
performed annually. In these patient groups, urgent 
Doppler renal ultrasound reevaluation should be per-
formed in case of acute worsening of BP control and/
or renal function.
8.3.3.2. Computed tomography angiography
Computed tomography angiography is indicated to 
confirm the diagnosis of renal artery stenosis (in 
patients with eGFR > 30 mL/min/1.73 m2). Normal 
CTA findings exclude a hemodynamically significant 
stenosis of the main renal artery. 
8.3.3.3. Magnetic resonance angiography
Magnetic resonance angiography is indicated to con-
firm the diagnosis of renal artery stenosis (recommen-
dation class I, level of evidence B). The most effective 
imaging sequence is three-dimensional gradient echo 
(3D GRE) following intravenous administration of 
a contrast agent. Contrast-enhanced MRA allows 
excluding a hemodynamically significant stenosis of 
the main renal artery. Paramagnetic contrast agents 
in doses used for magnetic resonance imaging (MRI) 
are not nephrotoxic. However, a possibility of neph-
rogenic systemic fibrosis in patients with renal dys-
function should be borne in mind. Gadodiamide, 
gadopentetate dimeglumine and gadoversetamide 
are contraindicated in patients with eGFR below 
30 mL/min/1.73 m2, including those on dialysis 
therapy and patients with acute kidney injury. In pa-
tients with eGFR 30–60 30 mL/min/1.73 m2, these 
contrast agents may be used provided that a 7-day 
interval between subsequent studies is maintained. 
Other paramagnetic contrast agents not listed above 
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may be used in patients with eGFR below 30 mL/
min/1.73 m2 provided that a 7-day interval between 
subsequent studies is maintained, and they may be 
used without these restrictions in patients with eGFR 
30–60 30 mL/min/1.73 m2. 
8.3.3.4. Invasive renal angiography
Invasive renal angiography is performed to image the 
renal artery and its branches. It involves introduction 
of a pigtail catheter to the aorta at the level of renal 
arteries and injecting an iodine contrast agent. This 
method allows very good visualization of both the 
main renal artery and accessory renal arteries, and 
particularly their origin from the aorta. Selective 
renal angiography using catheters with appropriately 
curved tips is also recommended. Invasive renal angi-
ography may be considered to confirm the diagnosis 
of renal artery stenosis in patients with a clinical 
suspicion of renal artery stenosis and equivocal non-
invasive imaging findings.
8.3.4. Management of atherosclerotic  
renal artery stenosis
Until now, no randomized study showed a signifi-
cant effect of interventional treatment on the course 
of hypertension, renal function, and cardiovascu-
lar event rate. The decision to implant a stent into 
a renal artery with an atherosclerotic stenosis should 
be based on multiple additional clinical factors and 
laboratory parameters, including the degree of BP 
control, presence and/or progression of renal dys-
function, and occurrence of the Pickering syndrome 
(unexplained flash pulmonary oedema). Decisions 
to proceed with invasive treatment and performance 
of revascularization procedures should be left to ap-
propriately experienced hypertension units.
The 2017 ESC guidelines do not recommend rou-
tine revascularization of atherosclerotic renal artery 
stenosis. According to these guidelines, balloon an-
gioplasty with or without stenting may only be con-
sidered in patients with atherosclerotic renal artery 
stenosis and recurrent unexplained congestive heart 
failure or flash pulmonary oedema, and in patients 
with bilateral renal artery stenosis and acute oligo- or 
anuric renal failure without renal atrophy.
In patients with unilateral renal artery stenosis, 
ACEI and ARB are effective in the treatment of hy-
pertension and may decrease progression of nephrop-
athy. Even in unilateral renal artery stenosis, however, 
treatment with ACEI or ARB requires caution and 
monitoring of renal function parameters. ACEI and 
ARB are contraindicated in bilateral renal artery ste-
nosis and renal artery stenosis in the single kidney. It 
is difficult to accept the opinion voiced in the 2017 
ESC guidelines that these drugs may also be used in 
the latter patient groups provided that they are toler-
ated (no adverse effect on the renal function) and the 
treatment is strictly monitored.
Diuretics, calcium antagonists, and b-blocker-
blockers are also effective in lowering BP to target 
values in patients with renal artery stenosis (with 
some reports indicating an adverse effect manifested 
by eGFR reduction in patients with bilateral renal 
artery stenosis).
All patients with atherosclerotic renal artery steno-
sis should be treated in accordance with the guide-
lines on secondary cardiovascular disease prevention. 
This includes use of antiplatelet and lipid-lowering 
therapies.
8.4. Renal artery stenosis due to  
fibromuscular dysplasia
The present section of the guidelines was developed 
based on the most recent First International Con-
sensus on the diagnosis and management of fibro-
muscular dysplasia (FMD), published in Journal of 
Hypertension and Vascular Medicine in early 2019.
8.4.1. Definition of fibromuscular dysplasia
Fibromuscular dysplasia is an idiopathic, segmental, 
non-atherosclerotic, and non-inflammatory vascular 
disease that leads to the development of stenoses in 
small- and medium-sized arteries. In addition to ath-
erosclerosis, FMD is the second most common cause 
of renal artery stenosis, responsible for about 10% 
of cases. The diagnosis and confirmation of FMD 
requires that the following conditions are excluded:
• renal artery spasm or artifacts during CTA imag-
ing; 
• atherosclerotic origin of arterial lesions; 
• inflammatory arterial disease; 
• monogenic arterial disease (e.g., neurofibroma-
tosis type I).
8.4.2. Clinical presentation
Fibromuscular dysplasia most commonly involves 
renal arteries and leads to the development of hy-
pertension. Cervicocephalic (carotid, vertebral and 
intracranial) arteries are the second most common 
location of FMD. However, FMD may be present in 
virtually all vascular beds, and is often concomitantly 
present in several areas in the vascular system. The 
arterial wall affected by FMD is prone to dissection 
and the development of aneurysms.
Renal artery dissection may have serious clinical 
consequences, leading to an acute development of 
severe hypertension, loss of kidney function, and 
renal infarction. In patients with FMD, dissection 
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may also involve other arteries, including carotid 
arteries (which may lead to stroke or TIA) and coro-
nary arteries (which may result in an acute coronary 
syndrome).
Based on radiological findings, arterial wall le-
sions typical for FMD are categorized as unifocal or 
multifocal.
The diagnosis of FMD requires that at least one 
unifocal or multifocal lesion is identified in the arte-
rial wall. 
If uni- or multifocal FMD lesions are present in 
one vascular bed, the presence of an aneurysm, dis-
section or tortuosity within another artery suggests 
a multivessel involvement. In contrast, an isolated 
presence of an arterial aneurysm, dissection or tortu-
osity is not sufficient for the diagnosis of FMD.
Indications for investigating a possibility of renal 
artery stenosis due to FMD in hypertensive patients 
include:
• age below 30 years, particularly in women;
• grade 3 hypertension (≥ 180/110 mm Hg), 
accelerated or malignant hypertension;
• resistant hypertension (BP above target values 
despite use of 3 antihypertensive medications in 
optimal doses, including a diuretic);
• unilateral small kidney without a previous history 
of uropathy;
• abdominal bruit without evidence of atheroscle-
rosis or its risk factors;
• established FMD in at least one other vascular bed.
Of note, no specific genetic testing for FMD is 
available, and genetic testing is not justified in as-
ymptomatic relatives of patients with FMD.
While awaiting further advances in genetic testing 
targeted at FMD, relatives of patients with FMD 
should currently undergo clinical evaluation and im-
aging to evaluate potentially involved vascular beds, 
particularly as suggested by clinical symptoms.
Symptoms and signs and laboratory test findings 
suggestive of renal artery stenosis due to FMD are 
summarized in Table XXXVII.
8.4.3. Investigations for renal artery stenosis  
due to fibromuscular dysplasia  
— screening and confirmatory tests
Doppler renal ultrasonography should be performed 
as a screening test for renal artery stenosis due to 
FMD in all hypertensive women of reproductive age, 
particularly those planning pregnancy.
While duplex ultrasound to evaluate renal arteries 
is used as a screening method in women of reproduc-
tive age (particularly those planning pregnancy), in 
patients with a suspicion of renal artery stenosis due 
to FMD (with indications for testing as outlined 
above) it remains a first-line imaging test only in 
tertiary care units with extensive experience with the 
use of this modality for the evaluation of the vascular 
system.
In patients with a suspicion of renal artery FMD, 
CTA remains the imaging test of choice, and MRA 
is the alternative imaging modality if CTA is contra-
indicated.
Imaging to identify FMD within renal, carotid, 
vertebral, and intracranial arteries should be consid-
ered if typical symptoms of FMD are present.
Invasive digital subtraction angiography of the 
renal arteries is recommended in patients with FMD 
confirmed by CTA or MRA if revascularization is 
clinically indicated. It may also be considered in pa-
tients with a high degree of suspicion of renal artery 
stenosis due to FMD if the diagnosis is uncertain 
based on non-invasive studies.
A separate issue is the choice of imaging modality 
in patients with suspected FMD in carotid, verte-
bral and intracranial arteries, as currently there is no 
evidence that would clearly favour any single modal-
ity. In most centres investigating for FMD, CTA or 
MRA remains the first-line imaging test.
In experienced centres, duplex ultrasound may 
be used for the initial evaluation of FMD in carotid 
arteries but it does not allow adequate assessment of 
distal segments of the internal carotid arteries, verte-
bral arteries, and intracranial arteries.
In patients with FMD, regardless of the presence 
and location of FMD lesions in various vascular 
beds, evaluation for intracranial aneurysms using 
CTA or MRA should be performed at least once.
It is also recommended that regardless of the loca-
tion of initially identified FMD lesions, patients with 
FMD undergo, at least once, imaging of the vascular 
system from the brain to the pelvis to identify FMD 
in other vascular beds and screen for asymptomatic 
aneurysms or dissections.
8.4.4. Management of renal artery stenosis  
due to fibromuscular dysplasia
Antiplatelet therapy (acetylsalicylic acid 75–100 
mg), if not contraindicated, is reasonable to prevent 
thrombotic and thromboembolic complications in 
patients with FMD.
Renal angioplasty is the treatment of choice for 
significant renal artery stenosis due to FMD (de-
fined as translesional pressure gradient of 10% of 
the mean aortic pressure, i.e., Pd/Pa < 0.90). Stent-
ing is not recommended, except for periprocedural 
dissection, primary renal artery dissection, or as 
a part of interventional treatment for renal artery 
aneurysm.
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Surgical treatment of significant renal artery ste-
nosis due to FMD should be considered in patients 
with:
• stenosis associated with a complex aneurysm; 
• recurrent stenosis after two unsuccessful angio-
plasty procedures;
• a lesion involving renal artery bifurcation and its 
branches.
In hypertensive patients with renal artery stenosis 
due to FMD in whom revascularization is not indi-
cated, appropriate follow-up is recommended:
• patients with FMD should undergo annual clini-
cal follow-up on an outpatient basis;
• long-term clinical follow-up in patients with 
FMD should include clinical evaluation, renal 
function testing (in patients with FMD within 
renal arteries), and imaging studies (with insuf-
ficient data to suggest a specific algorithm for 
imaging during long-term clinical follow-up in 
patients with FMD); 
• it seems reasonable to suggest that the extent of 
imaging — taking into account local availability 
of imaging modalities — should be determined 
individually based on the severity of FMD, the 
need to monitor progression of FMD compli-
cations (aneurysm or dissection), and previous 
revascularization procedures;
• in patients after spontaneous coronary artery 
dissection, imaging of the whole arterial system 
from the brain to the pelvis using CTA or MRA 
should be performed at least once to evaluate the 
presence of FMD and its complications in non- 
-coronary arteries.
8.5. Primary hyperaldosteronism
8.5.1. Definition and prevalence
Primary hyperaldosteronism (PHA) is defined as 
a hormonally mediated form of hypertension caused 
by autonomous aldosterone production. Using this 
definition, PHA is diagnosed by showing that aldo-
sterone level is unaffected by factors that affect its 
production in physiological conditions.
Primary hyperaldosteronism is not a pathogeneti-
cally uniform condition, and several forms of PHA 
are distinguished depending on the hormonal profile 
and the management approach:
• bilateral adrenal hyperplasia;
• adrenal cortex adenoma;
• familial hyperaldosteronism type I, II, III or IV;
• aldosterone-producing adrenal carcinoma;
• ectopic aldosterone production (by neoplastic 
tissue).
The prevalence of PHA in hypertensive patients 
depends on BP values. In the general hypertensive 
population, PHA is present in up to 7% of patients 
(depending on the definition of PHA), while the 
prevalence of PHA in patients with resistant hyper-
tension has been estimated at 6–23%.
8.5.2. Clinical presentation
Compared to patients with primary hypertension, 
patients with PHA have been found to have more 
frequent target organ damage such as left ventricular 
hypertrophy, increased carotid artery intima-media 
thickness, reduces arterial compliance, and microal-
buminuria.
An adverse effect of aldosterone excess on the 
cardiovascular system has been highlighted, result-
ing primarily in myocardial, vascular, and renal 
damage. Myocardial hypertrophy and fibrosis lead 
to diastolic dysfunction, which may result in overt 
heart failure and is a substrate for arrhythmia (such 
as atrial fibrillation provoked by concomitant hy-
pokalaemia).
In patients with PHA, the cardiovascular risk 
is significantly increased. Multiple studies showed 
a largely increased risk of coronary artery disease, 
myocardial infarction, heart failure, atrial fibrillation, 
and stroke in this population compared to matched 
patients with primary hypertension. 
Symptoms and signs and laboratory test findings 
suggestive of PHA are summarized in Table XXXVII.
According to the Endocrine Society guidelines, 
investigations for PHA should be considered in pa-
tients:
• with BP values above 150/100 mm Hg in each 
of three measurements during separate visits (ac-
cording to the 2019 PTNT guidelines expert 
panel, investigations for PHA should be consid-
ered in patients with grade 2–3 hypertension); 
• with resistant hypertension; 
• with spontaneous or diuretic-induced hypoka-
laemia; 
• with hypertension and incidentally discovered 
adrenal tumour; 
• with hypertension and OSA; 
• with hypertension and a family history of early 
onset hypertension or a cerebrovascular event at 
a young age (< 40 years);
• in all hypertensive first-degree relatives of patients 
with established PHA. 
In addition, investigations for PHA should be 
considered if the severity of target organ damage is 
disproportionate to the severity of hypertension.
8.5.3. Screening for primary hyperaldosteronism
The primary screening test for PHA is evaluation of 
the aldosterone-to-renin ratio (ARR). When evaluat-
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ing and interpreting ARR, the following should be 
taken into consideration:
• in patients with hypokalaemia, potassium level 
should be brought to normal values by adequate 
supplementation, and dietary sodium intake 
should also be controlled (normal sodium diet);
• antihypertensive drug therapy should be appro-
priately modified:
 — drugs that significantly affect ARR should be 
withdrawn 4 weeks before testing, including spi-
ronolactone, eplerenone, triamterene, amiloride, 
thiazide/thiazide-like diuretics, and loop diuret-
ics,
 — if ARR is nondiagnostic and hypertension may 
be adequately controlled using drugs that do not 
affect ARR (see below), the following medica-
tions should be withdrawn 2 weeks before test-
ing: b-blockers, central a2-agonists (clonidine, 
methyldopa), nonsteroidal anti-inflammatory 
drugs (false-positive ARR), and ACEI, ARB, re-
nin inhibitors, and dihydropyridine calcium an-
tagonists (false-negative ARR),
 — drugs that have the least effect on ARR should 
be used to control hypertension, including vera-
pamil, hydralazine, doxazosin, prazosin, and tera-
zosin; however, some authors do not recommend 
using verapamil due to a potential effect on ARR 
in patients with adrenal adenoma and a somatic 
KCJN5 gene mutation;
 — in some situations, due to high BP values and 
concomitant conditions, appropriate modifica-
tion of antihypertensive drug therapy is not possi-
ble and may be even associated with an increased 
cardiovascular risk; in these circumstances, the 
effect of drug therapy used in the patient should 
be taken into account; 
• blood sampling for ARR should be performed 
in a sitting position between 9 and 10 AM, with 
the patient remaining upright (sitting, stand-
ing, walking) for 2–4 hours before blood col-
lection, and the collected blood samples should 
be handled appropriately as agreed with the 
laboratory;
• due to the fact that interpretation of ARR is 
based on values considered abnormal in previous 
research studies and not the reference ranges for 
the assays used in the laboratories, ARR should 
be determined in laboratories in which the assays 
for aldosterone and plasma renin activity or renin 
level have been validated against the laboratories 
that have appropriate experience in the diagnosis 
of PHA;
• most commonly, the ARR value suggesting PHA 
is defined as:
 —  above 30 (aldosterone level in ng/dL and plasma 
renin activity in ng/mL/h); or
 — above 750 (aldosterone level in pmol/L and plas-
ma renin activity in ng/mL/h),
 — for an elevated ARR to suggest PHA, plasma 
aldosterone level must be at least moderately 
increased [e.g., >15 ng/dL (150 pg/mL or 416 
pmol/L)],
 — ARR is also much affected by the lower limit of 
detection of plasma renin activity by a given as-
say, which may be different for different assays 
and laboratories (plasma renin activity value used 
for calculating ARR should not be lower than 0.2 
ng/mL/min),
 — in the recent years, commercial assays for plasma 
renin level (direct renin concentration) have been 
introduced; ARR conversion coefficient for renin 
level should be determined separately for each 
assay;
• other factors that may affect ARR value interpre-
tation should also be taken into account, includ-
ing age (low-renin essential hypertension in the 
elderly), creatinine level, concomitant conditions, 
difficult blood sampling, and use of hormonal 
drugs (e.g., oestrogen-containing preparations are 
associated with false-positive ARR values).
8.5.4. Confirmatory tests
The diagnosis of PHA is confirmed by establishing 
no effect of factors that normally decrease plasma 
aldosterone level or 24-hour urinary aldosterone ex-
cretion. In clinical practice, the two most commonly 
used tests are captopril suppression test and saline 
suppression test (with intravenous infusion of 2 litres 
of normal saline).
8.5.5. Differentiation between various forms 
of primary hyperaldosteronism
After the diagnosis of PHA has been established 
based on clinical symptoms and biochemical test 
findings, it is necessary to assess the nature and loca-
tion of adrenal lesions. Various forms of PHA, in 
particular bilateral adrenal hyperplasia and adrenal 
adenoma, should also be differentiated.
Computed tomography (CT) is currently the 
standard method to evaluate adrenal lesions. Its sen-
sitivity for detecting adrenal tumours exceeds 90%. 
CT allows assessment of the morphology of detected 
adrenal tumours.
Adrenal venous sampling is the method of choice 
for differentiating between various forms of PHA. 
It is indicated in all patients in whom adrenalec-
tomy is considered. Exceptions include young pa-
tients (< 35–40 years of age) with a typical adenoma 
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on CT/MRI and normal contralateral adrenal gland 
who may be referred for surgery based on imaging 
only. However, many centres perform adrenal venous 
sampling also in such patients.
8.5.6. Management of primary 
hyperaldosteronism
In documented unilateral PHA due to an aldoste-
rone-producing adenoma or unilateral adrenal hy-
perplasia, the treatment of choice is unilateral lapa-
roscopic adrenalectomy, while patients with bilateral 
adrenal disease (idiopathic adrenal hyperplasia or bi-
lateral adenomas) should be treated with aldosterone 
antagonists. Glucocorticoid-remediable aldosteron-
ism should be treated with low doses of a long-acting 
glucocorticosteroid, e.g., dexamethasone.
In patients with bilateral adrenal disease and those 
with unilateral PHA who did not undergo adrenal-
ectomy for various reasons, aldosterone antagonists 
are indicated. The initial spironolactone dose should 
be 12.5–25 mg once daily. The lowest effective dose 
should be determined by a gradual dose increase to 
100 mg per day or more. To avoid high spirono-
lactone doses, which may result in adverse effects, 
a thiazide diuretic, amiloride, or triamterene may be 
added. Eplerenone is a newer, selective mineralocor-
ticoid receptor antagonist characterized by a weaker 
antiandrogenic effect and a weaker agonist effect on 
the progesterone receptor, and thus it is associated 
with a lower rate of adverse effects. The strength of its 
mineralocorticoid receptor antagonist effect has been 
estimated at 60% of that of spironolactone. Due to 
a shorter duration of action, this drug should be ad-
ministered more frequently than once daily (initially 
25 mg twice daily). However, eplerenone has not 
been licensed to treat PHA in the European Com-
munity.
8.6. Catecholamine-producing tumours
8.6.1. Definition
Adrenal catecholamine-producing tumours are 
known as phaeochromocytomas, and the remaining 
extra-adrenal chromaffin cell tumours, which may 
also be hormonally active, are known as paraganglio-
mas. Collectively, these are called phaeochromocyto-
mas-paragangliomas (PPGL).
8.6.2. Clinical presentation
The most common symptoms, usually paroxysmal in 
nature, include:
• paroxysmal BP surges (with typically large BP 
variation) which may last from several minutes 
to several hours;
• chronic hypertension;
• headache;
• excessive sweating;
• palpitation;
• pallor;
• tremor;
• anxiety;
• orthostatic hypotension.
Elevated glucose level may be found on bio-
chemical testing. ABPM may show large BP varia-
tion and a decreased nocturnal BP fall, or even 
a non-dipping BP pattern and BP elevation during 
the night.
The provoking factors include exercise, abdomi-
nal pressure, large meals, some medications [ephed-
rine, phenylephrine, adrenocorticotropic hormone 
(ACTH), phenothiazines, amphetamine, metoclo-
pramide, tricyclic antidepressants, some anaesthesia 
drugs], stress, and alcohol intake. Catecholamine 
release by the tumour may also be induced by gluco-
corticosteroid administration. Phaeochromocytomas 
may also remain asymptomatic (including with nor-
mal BP values).
8.6.3. Investigations for catecholamine-producing 
tumours
Indications for investigations for PPGL include:
• symptoms suggestive of PPGL, particularly if epi-
sodic in nature;
• medication-induced PPGL symptoms;
• an incidentally detected adrenal tumour (with or 
without hypertension);
• a gene mutation predisposing to PPGL or clinical 
evidence of a hereditary PPGL syndrome;
• a history of PPGL.
The major diagnostic criterion for a hormonally 
active PPGL is the finding of an elevated catechol-
amine metabolite serum level or urinary excretion, 
followed by tumour localization by imaging studies. 
The final diagnosis is based on histopathologic assess-
ment of the resected tumour.
Plasma free metanephrines and urinary fraction-
ated metanephrines are considered the most useful 
(i.e., most sensitive) biochemical tests. The high-
est sensitivity was reported for plasma free meta-
nephrines (sensitivity 97–99%, specificity 82%). 
Urinary adrenaline and noradrenaline excretion 
is characterized by lower sensitivity and specific-
ity, and the least diagnostic utility was shown 
for measurements of urinary vanillylmandelic acid 
and dopamine and plasma catecholamines. In rare 
cases, the clonidine suppression test may be per-
formed.
Anatomical imaging studies in patients with 
PPGL should be performed after excessive catechol-
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amine and/or their metabolite levels have been iden-
tified in plasma or urine. Localization studies for 
PPGL are also performed in PPGL gene mutation 
carriers. Useful imaging methods for PPGL include 
CT and MRI.
8.6.4. Management of catecholamine-producing 
tumours
Paroxysmal BP surges caused by catecholamine-pro-
ducing PPGL may be best managed by administering 
phentolamine intravenously, usually at the dose of 
2–5 mg repeated as needed.
Surgical removal of catecholamine-producing 
PPGL is the treatment of choice.
Appropriate preoperative patient prepara-
tion is important to reduce BP values, lower the 
heart rate, and control paroxysmal BP surges and 
other symptoms related to the excess of circulat-
ing catecholamines. For this purpose, a-blockers 
are administered orally for 2–3 weeks, including 
phenoxybenzamine (in increasing doses starting 
from 10 mg twice daily up to 1 mg/kg/day in 2–3 
divided doses) or doxazosin (in gradually increas-
ing doses starting from 2 mg up to 32 mg/day 
in 1–2 divided doses). If a-adrenergic receptor 
blockade is unsuccessful at controlling BP, a cal-
cium antagonist (nifedipine or amlodipine) may 
be added as the second antihypertensive medica-
tion. In patients with significant tachycardia, ad-
dition of a cardioselective b-blocker is desirable 
but only after a-adrenergic receptors have been 
blocked. Catecholamines released by PPGL act on 
both a- and b-adrenergic receptors. Administering 
a b-blocker without previous a receptor blockade is 
contraindicated as it may lead to excessive a recep-
tor activation and a significant BP rise. Combined 
a- and b-adrenergic receptor blockers (labetalol 
and carvedilol) should not be used. Correcting 
hypovolemia by adequate sodium and fluid intake 
to avoid orthostatic hypotension is also important 
during preoperative patient preparation.
8.6.5. Long-term care of patients 
with catecholamine-producing tumours
Following surgical PPGL removal, long-term patient 
follow-up is necessary that should include monitor-
ing of BP values and plasma or urinary metaneph-
rines. The initial postoperative evaluation to allow 
early identification of a possible tumour recurrence 
or development of hormonally active metastases 
should be undertaken depending on the overall clini-
cal picture (genetic predisposition, tumour size, mul-
tiple tumours) at 6–12 months and then repeated 
annually.
8.6.6. Genetic testing in patients 
with catecholamine-producing tumours
The proportion of genetic forms of PPGL is current-
ly estimated at 30–40%. Genetic testing for known 
mutations associated with PPGL is recommended in 
all PPGL patients. Modern genetic assay technolo-
gies allow testing for several PPGL-associated genes 
in a single sample.
8.7. Other rarer forms of secondary 
hypertension
Other rare forms of secondary hypertension, such 
as renin-secreting tumours, coarctation of the aor-
ta, and Cushing syndrome, are summarized in Ta-
ble XXXVII.
9. Recommendations on the diagnostic 
and therapeutic management of 
hypertension in children and adolescents
Hypertension is a major potentially modifiable car-
diovascular risk factor. It is also a major clinical prob-
lem in adult medicine, and one of the most common 
chronic conditions in adolescents. In addition to 
the primary form, hypertension is also an important 
complication of other chronic conditions such as 
diabetes type 1 and 2, chronic kidney disease, coarc-
tation of the aorta, congenital adrenal hyperplasia, 
and others. Although diabetes type 2 is relatively 
uncommon in Caucasian children and adolescents, 
children with overweight and obesity, and particu-
larly those with carbohydrate intolerance and insulin 
resistance should be considered a potential risk group 
for hypertension. Another important problem is hy-
pertension in children and adults born prematurely, 
particularly before 33 weeks of gestation, or as small 
for gestational age newborns.
The current guidelines are expanded and updated 
2015 PTNT paediatric recommendations, previ-
ously presented in an expanded version in 2016 as 
The Children’s Memorial Health Institute (IP-CZD) 
recommendations. The current edition of the PTNT 
paediatric recommendations has been developed 
based on the previously published fourth report of 
the National High Blood Pressure Education Pro-
gram Working Group on Children and Adolescents 
(hereafter referred to as the Fourth Report), 2009 
and 2016 paediatric ESH guidelines, ESC guide-
lines, AHA guidelines, 2017 American Academy of 
Paediatrics (AAP) guidelines, literature review, and 
expert opinion. Detailed recommendations were also 
based on the current recommendations of the respec-
tive society working groups.
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Compared to the 2015 paediatric PTNT recom-
mendations, the present edition includes extended 
epidemiological data on the prevalence and inci-
dence of hypertension, extended or modified sec-
tions on the evaluation of target organ damage, 
hypertension in children with diabetes or chronic 
kidney disease, and a section on diagnostic and ther-
apeutic challenges. A section has also been added 
on the approach to early diagnosis of hypertension 
during postdischarge care for children born below 
33 weeks of gestation, as recommended in 2018 
by the Polish Neonatal Society. Another important 
novelty is the current classification of hypertension, 
presented earlier in the 2016 ESH guidelines and 
2016 IP-CZD guidelines.
Problems with defining target BP values have been 
discussed in a new subsection. The chapter on BP 
measurement principles includes new recommen-
dations regarding BP measurements in newborns, 
neonates, and infants. References have been updated 
and expanded.
9.1. Epidemiology of hypertension in children 
and adolescents
Data from representative population studies indicate 
that hypertension is present in 3–5% of children 
and adolescents aged 0–18 years. In the OLAF and 
OLA studies, conducted in representative popula-
tion samples, BP values above the 95th percentile for 
age and gender, calculated as the mean of the second 
and third BP measurement during a single visit, were 
noted in 6.9% of children aged 3 years, 7.7% of 
children aged 6–10 years, and 6.2% of youths aged 
10–20 years.
The prevalence of hypertension among adoles-
cents 14–18 years of age, defined in 18-year-olds 
using the adult definition, i.e., BP ≥ 140/90 mm Hg, 
is 10–13%, similarly to that among young adults. 
Starting from puberty, hypertension is 3–4 times 
more prevalent in boys compared to girls. This gen-
der difference is maintained until the fifth decade 
of life and is associated with a physiological BP rise 
during puberty in boys. In risk groups, such as obe-
sity, chronic kidney disease, and diabetes type 1 and 
2, the prevalence of hypertension is much higher 
ranging from 5–25% (diabetes type 1) to 30–40% 
(diabetes type 2). Prematurity and low birth weight 
are associated with a particular risk of developing 
hypertension. It has been estimated that at 3 years of 
age, hypertension in present 7.3% of children born 
prematurely. The risk of developing hypertension 
increases with younger gestational age at birth and 
is particularly high in persons born below 33 weeks 
of gestation.
Secondary hypertension is the major cause of hy-
pertension in younger children. The higher rates of 
obesity in children and adolescents, the more com-
mon is primary hypertension which accounts for 
50% of all hypertension cases in this age group.
9.2. Recommendations regarding screening  
for hypertension
According to the 2009 and 2016 ESH guidelines 
and the Fourth Report, BP should be measured in 
children above 3 years of age at least once a year 
during routine health supervision visits and visits 
related to health problems. In children below 3 years 
of age, BP measurement is recommended in selected 
cases in children with identified health problems 
(Tab. XXXVIII). Screening for hypertension in chil-
dren below 24 months of age is not supported by so-
ciety guidelines and epidemiological study findings, 
as BP measurements in younger children are at a high 
risk of failure due to lack of patient cooperation: the 
proportion of unreliable BP measurements is 41% in 
children at one year of age, 20% in children aged 3 
years, and 9% of children aged 3–6 years.
9.3. Diagnosis of hypertension
9.3.1. Definitions and classification 
of hypertension in children and adolescents
According to the generally accepted definition of 
hypertension in children, this diagnosis requires 
BP readings ≥ 95th percentile for age, gender, and 
height during three independent measurements. 
A term “elevated blood pressure” has also been used 
in the literature to denote children with single BP 
values above 95th percentile, which is not suffi-
cient for the diagnosis of hypertension. However, 
the meaning of the term “elevated blood pressure” 
changed when the 2017 AAP guidelines used this 
term to denote BP values previously categorized as 
prehypertension.
Classification of hypertension in children and ado-
lescents depends on the method of BP measurement. 
Due to diverging opinions on interpreting BP 
values in adolescents (see below), use of the adult 
BP classification is recommended in adolescents 
≥ 16 years of age. Based on office measurements 
(using the auscultatory or oscillometric method), the 
following categories are distinguished (Tab. XXXIX):
• normal BP — BP values below the 90th percen-
tile for age, gender, and height; in adolescents ≥ 
16 years of age, normal BP is < 130/85 mm Hg;
• high normal BP (Europe) or elevated BP 
(United States) — SBP and/or DBP between the 
90th and 95th percentile, and BP 130–139/85–89 
mm Hg in adolescents ≥16 years of age (note: in 
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the AAP classification, elevated BP is defined as 
values up to 129/80 mm Hg);
• hypertension — mean SBP and/or DBP values 
≥ 95th percentile for age, gender, and height based 
on at least three independent measurements; in 
adolescents ≥ 16 years of age, the threshold for 
the diagnosis of hypertension is the same as in 
adults, i.e., ≥140/90 mm Hg;
• white coat hypertension — office BP measure-
ments above the 95th percentile, or ≥ 140/90 mm 
Hg in adolescents ≥ 16 years of age but home BP 
or ABPM values within normal limits;
• grade 1 hypertension — BP values be-
tween the 95th percentile and 5 mm Hg above 
the 99th percentile for age, gender, and height, 
or 140–159/90–99 mm Hg in adolescents 
≥ 16 years of age;
• grade 2 hypertension — BP values more than 5 
mm Hg above the 99th percentile for age, gender, 
and height, or 160–179/100–109 mm Hg in ad-
olescents ≥ 16 years of age; as use of the adult BP 
classification is recommended in the latter group, 
BP ≥ 180/110 mm Hg is categorized as grade 3 
hypertension in adolescents ≥ 16 years of age;
• isolated systolic hypertension — SBP values 
≥ 95th percentile but DBP values < 90th percentile, 
or SBP ≥ 140 mm Hg but DBP < 90 mm Hg in 
adolescents ≥ 16 years of age.
Categories of severe hypertension and hyperten-
sive urgencies and emergencies have not been defined 
Table XXXVIII. Blood pressure measurements in children and adolescents — indications and technique
BP should be measured in all children aged ≥ 3 years at least once a year and during any routine physician examination
• BP measurement is more reliable if the child has not eaten a meal within 30 minutes before the measurement, has not received medications 
that might affect BP, and has been resting in a sitting position with its back supported in a quiet environment for 5–10 minutes before the mea-
surement
• During the initial consultation, BP should be measured on all four limbs. During the first year of life and until the child assumes the upright posi-
tion, BP readings in the lower limbs are lower than in the upper limbs. During the second year of life in a child who stands/walks, BP readings in 
the lower limbs are higher by about 20 mm Hg, and at a later age they are higher by about 30–40 mm Hg
• Subsequent measurements should be performed on the right arm that is fully exposed, abducted and supported at the level of the heart
• The cuff should encircle the full circumference of the arm and cover at least two thirds of its length. The inflatable bladder should encircle at le-
ast 80% of the arm circumference, including the whole medial aspect of the arm. BP may be overestimated by as much as 30% if the cuff is too 
narrow, and underestimated if the cuff is too wide
• In infants, the body position has no significant effect on BP values. During sleep, SBP values in infants are lower by 5–7 mm Hg
• As readings obtained during the first measurement are usually overestimated, BP should be measured 2–3 times during a single examination
• BP readings above the 90th percentile by the oscillometric method require verification by the auscultatory method
• If the BP difference between the upper limbs is ≥ 5 mm Hg, this fact should be noted in the medical record
In younger children ( < 3 years), BP should be measured in specific situations including:
• perinatal morbidity: prematurity, low birth weight, intensive therapy in the perinatal period
• congenital anomalies
• recurrent urinary tract infections, kidney and/or urinary tract disease
• malignancy
• solid organ or bone marrow transplantation
• use of drugs affecting BP
• symptoms and conditions associated with hypertension (neurofibromatosis, tuberous sclerosis, others), intracranial pressure rise
BP — blood pressure; SBP — systolic blood pressure
Table XXXIX. Blood pressure classification in children and adolescents based on office blood pressure measurements
0–16 years of age  ≥ 16 years of age
BP category SBP and/or DBP percentiles SBP and/or DBP values
Normal BP  < 90th percentile  < 130/85 mm Hg
High normal BP/prehypertension  ≥ 90th and < 95th percentile 130–139/85–89 mm Hg
Hypertension  ≥ 95th percentile  ≥ 140/90 mm Hg
   Grade 1 hypertension 95th to 99th percentile + 5 mm Hg 140–159/90–99 mm Hg
   Grade 2 hypertension  > 99th percentile + 5 mm Hg 160–179/100–109 mm Hg
   Grade 3 hypertension  ≥ 180/110 mm Hg
Isolated systolic hypertension SBP ≥ 95th percentile 
and DBP < 90th percentile
SBP ≥ 140 
and DBP < 90 mm Hg
BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure
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in the classifications of hypertension in children that 
were adopted in European and U.S. guidelines. 
However, the following definitions of these condi-
tions are used for practical reasons:
• severe hypertension — BP values more than 30 
mm Hg above the 99th percentile for age, gender, 
and height;
• hypertensive urgencies — impending organ 
failure related to hypertension, requiring rapid 
intervention, usually with concomitant unspecific 
symptoms such as headache and vomiting;
• hypertensive emergencies — established or 
acute organ damage related to hypertension, 
mostly with organ failure, symptoms of encepha-
lopathy, and Keith-Wagener-Barker grade 3 and/ 
/or grade 4 retinopathy on fundoscopy.
• malignant hypertension — in the past, this 
term was used to describe sudden BP increase 
with grade 3 and/or grade 4 retinopathy on fun-
doscopy, consistent with a hypertensive emer-
gency in the present classification. According to 
the nomenclature in the 2016 paediatric ESC 
guidelines, malignant hypertension is defined as 
sudden BP increase with evidence of damage to 
at least three organs, or with concomitant mi-
croangiopathy. In practice, this definition is met 
by hypertension accompanying acute haemolytic-
uraemic syndrome;
• resistant hypertension — hypertension that is 
not controlled despite treatment with three anti-
hypertensive drugs including a diuretic.
The classification of hypertension based on ABPM 
also includes the category of masked hypertension, 
defined as abnormal BP values in ABPM and normal 
BP values in office measurements (Tab. XL). As simi-
larly to office BP measurements, 95th percentile BP 
values by ABPM may exceed values considered nor-
mal in adults, the 2016 ESH guidelines recommend 
using 95th percentile-based threshold values in chil-
dren and adolescents as long as they do not exceed 
the upper limit of normal values in adults. If 95th per-
centile BP values exceed normal values in adults, it 
is recommended to use adult thresholds, i.e. 130/80 
mm Hg for the 24-hour mean, 135/85  mm  Hg 
for the daytime mean, and 120/70 mm Hg for the 
night-time mean.
9.3.2. Reference blood pressure values
9.3.2.1. Reference values for office measurements
It is recommended to use reference BP values for 
a given age, gender and height developed for specific 
BP measurement methods (auscultatory, oscillomet-
ric). For BP measurements using the auscultatory 
method, the most commonly used are reference val-
ues for children aged 0–18 years, developed for the 
population of the United States, Canada, Mexico, 
and Great Britain and published in the Fourth Re-
port. For oscillometric (automated) BP measure-
ments, reference values developed for the Polish 
population of children aged 3–18 years are recom-
mended. As automated measurements are most com-
monly performed in everyday paediatric practice, 
these norms have been included in the new Polish 
child’s health record book (2016).
9.3.2.2. Home blood pressure measurements
In children with the diagnosis of hypertension, home 
BP measurements using a validated oscillometric 
device are recommended (https://nadcisnienietet-
nicze.pl/dla_lekarzy/zalecenia_i_standardy/zalece-
nia_ptnt). Use of the reference values developed by 
Table XL. Blood pressure classification in children based on ambulatory blood pressure monitoring*
Category Office BP Mean SBP and/or DBP by ABPM SBP and/or DBP load
Normal BP  < 90th percentile  < 95th percentile  < 25%
White coat hypertension  ≥ 95th percentile  < 95th percentile  < 25%
Masked hypertension  < 95th percentile  ≥ 95th percentile  < 25%
High normal BP  ≥ 90th percentile and/or 120/80 mm Hg  < 95th percentile 25–50%
Ambulatory hypertension  ≥ 95th percentile  ≥ 95th percentile 25–50%
Severe ambulatory hypertension  ≥ 95th percentile  ≥ 95th percentile  > 50%
*In patients ≥ 16 years of age, it is recommended to use adult cut-off values, i.e., 130/80 mm Hg for the 24-hour mean BP, 135/85 mm Hg for the daytime period and 120/70 mm Hg for the night-time period; 
ABPM — ambulatory blood pressure monitoring; BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure
Table XLI. Reference home blood pressure values in boys and 
girls (95th percentile)
Height [cm] Girls Boys
120−129 119/74 119/76
130−139 120/76 121/77
140−149 122/77 125/77
150−159 123/77 126/78
160−169 124/78 128/78
170−179 125/79 132/78
180−189 128/80 134/79
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Stergiou et al. for children and adolescents aged 6–18 
years is recommended (Tab. XLI). No reference BP 
values were developed for HBPM in younger chil-
dren. Evaluation based on BP measurements twice 
daily during at least 3 days, at equal intervals and be-
fore administration of antihypertensive medications, 
is considered reliable. It is recommended to perform 
2–3 measurements at short intervals and record the 
last measurement. The optimal approach involves 
morning and evening BP measurements performed 
during 7 subsequent days. Adequate home BP mea-
surements are considered a reliable indicator of the 
effectiveness of antihypertensive therapy.
9.3.2.3. Ambulatory blood pressure measurement
Ambulatory BP measurement using a validated oscil-
lometric device is recommended in all children above 
5 years of age in whom hypertension was diagnosed 
based on office BP measurements. Use of the refer-
ence BP values for ABPM developed by Wühl et 
al. and adopted in the 2014 AHA guidelines is rec-
ommended, and references values for adults should 
be used in adolescents ≥ 16 years of age. Routine 
repeated ABPM is recommended to evaluate treat-
ment effects.
9.3.3. Principles of blood pressure measurement
The technique of BP measurements is summarized 
in Table XXXVIII. Both automated (oscillometric) 
and auscultatory method may be used for routine 
measurements, and auscultatory method is used for 
confirming hypertension identified by automated 
measurements. Different principles apply to neo-
nates and infants in whom auscultatory measure-
ments are technically difficult and associated with 
a more pronounced white coat effect compared to 
automated (oscillometric) measurements. In this 
age group (up to 3–4 years of age), repeated auto-
mated measurements at short intervals are recom-
mended. In addition, when BP measurements are 
indicated in newborns and neonates, they should 
follow the protocol described in the section Neona-
tal hypertension.
9.3.3.1. Interpretation issues
When interpreting BP measurements, age, gender, 
and height of the patient should be taken into con-
sideration. Significant issues have been raised for ne-
onates (see “Neonatal hypertension” below), children 
in the first year of life, and adolescents, as well as 
interpretation of oscillometric measurements includ-
ing ABPM. In neonates and children in the first year 
of life in whom BP has been measured, evaluation of 
SBP only is recommended.
Of note, the 95th percentile SBP values for girls 
aged 13–18 years are much lower compared to those 
for boys, and at the age of 18 years, the 95th  percen-
tile values for both SBP and DBP in girls are 5–10 
mm Hg lower than 140/90 mm Hg. The latter values 
correspond to 99th percentile in girls aged 18 years. 
Another phenomenon in adolescents is isolated sys-
tolic hypertension, seen particularly in boys without 
significant additional risk factors, frequently partici-
pating in sports. In these cases, spurious hyperten-
sion should be considered, with elevated SBP only in 
peripheral arteries, such as brachial artery, but nor-
mal central BP. No evidence of target organ damage 
is seen in these patients. For this reason, exposure to 
cardiovascular risk factors (intermediate phenotype) 
and the presence of subclinical target organ damage 
should also be considered when interpreting BP val-
ues (see below).
As most currently used ABPM devices are based 
on the oscillometric method, it should be empha-
sized that with this method, the mean arterial pres-
sure (MAP) is directly evaluated, and SBP and DBP 
values are calculated using appropriate algorithms. In 
addition, results of some controlled paediatric studies 
(e.g., the ESCAPE study) and therapeutic recom-
mendations (see below) are based on the analysis of 
MAP values. Another interpretation issue related to 
ABPM is the fact that using this method, higher BP 
values compared to office measurements are obtained 
in children below 10 years of age and those with the 
height below 120 cm. Due to lacking reference values 
and the above mentioned interpretation issues, rou-
tine use of ABPM is not recommended in children 
below 5 years of age.
In turn, 95th percentile values in tall children and 
adolescents may exceed BP considered normal in 
adults. These problems led to a change in the defini-
tion and classification of hypertension in adolescents 
≥ 16 years of age (see: Diagnosis of hypertension).
9.3.3.2. Problems with defining target blood pressure 
values in children receiving antihypertensive treatment
The hypertension literature, including the ESH 
guidelines, the Fourth Report, the AAP guidelines, 
and expert opinions, defines threshold BP values for 
the diagnosis of hypertension and target BP values 
during treatment. These values differ, i.e., while the 
diagnosis of hypertension is defined as BP ≥ 95th 
percentile, it is also recommended to lower BP below 
the 90th percentile in patients without concomitant 
conditions. However, setting these target BP val-
ues during treatment should also be associated with 
a change in the definition of hypertension by setting 
a lower threshold for the diagnosis, i.e., the 90th 
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percentile. This also necessitates defining the man-
agement in subjects with BP values in the 90–95th 
percentile range. 
The current approach generates interpretation is-
sues as it implies initiating treatment in children with 
BP values in the 90–95th percentile range. While 
non-drug therapy is not a problem, drug therapy 
should also be considered in those with BP values 
persistently in the high normal range despite non-
drug therapy. Thus, a change in the definition of 
hypertension would be logical.
Indirect evidence in favour of setting target BP 
threshold at the 90th percentile in children with pri-
mary hypertension without concomitant conditions 
has been provided by studies in adult hypertensives, 
in particular the SPRINT trial and a 2016 meta-
analysis that evaluated the efficacy of antihyperten-
sive treatment in risk groups such as chronic kidney 
disease and diabetes. Arguments in favour of setting 
both the definition of hypertension in children and 
the target BP threshold at the 90th percentile have 
also been provided by the Cardiovascular Risk in 
Young Finns Study results. In this study, signifi-
cantly higher BP values and higher arterial stiffness, 
as evaluated by the pulse wave velocity, were noted 
in adults who had high normal BP (i.e., 90–95th 
percentile range) in childhood and adolescence com-
pared to those who had BP < 90th percentile in child-
hood and adolescence. In the 2017 AAP guidelines, 
new definitions of hypertension were recommended 
based on the SPRINT trial results. Lower target 
BP values (< 90th percentile or < 130/80 mm Hg) 
were also recommended in children with essential 
hypertension, with an argument that lowering BP 
below these thresholds leads to a further reduc-
tion in the rate of left ventricular hypertrophy. It 
should be noted, however, that the mean age in 
the SPRINT study was 67 years, and the partici-
pants were subjects with concomitant conditions 
who already received antihypertensive treatment. In 
addition, the method of BP measurements differed 
from those used in routine clinical practice. Further-
more, the studies cited in the AAP guidelines do not 
support further reduction in left ventricular mass 
(LVM) in children in whom BP was lowered below 
the 90th percentile. It should also be noted that in 
children and adolescents with primary hypertension, 
the strongest predictor of a reduction of LVM and 
the rate of left ventricular hypertrophy is not BP 
lowering but a reduction in visceral fat, as assessed 
by a reduction in waist circumference and normal-
ization of metabolic disturbances. For this reason, 
target BP < 95th percentile (or < 140/90 mm Hg) 
has been recommended in the present guidelines in 
children and adolescents with primary hypertension 
without concomitant conditions.
At the same time, the present guidelines recom-
mend intensive non-drug treatment as the primary 
management strategy in essential hypertension.
Similar issues arise regarding the threshold for the 
diagnosis of hypertension and recommended target 
BP values in children with chronic kidney disease 
and diabetes. In paediatric patients with chronic kid-
ney disease, drug treatment is recommended with BP 
values above the 90th percentile, and the target BP 
values depend on the presence of proteinuria. The 
current recommendations are based on the ESCAPE 
study results which showed that in children with 
proteinuria > 0.5 g/d, reducing MAP by ABPM 
below the 50th percentile is beneficial. Such benefits 
were not shown, however, in children with less severe 
proteinuria or without proteinuria. Despite this, the 
ESH guidelines and other expert opinions (presented 
in review articles) suggest target BP values below the 
75th percentile in such cases. However, even studies 
cited in these documents do not offer any support for 
such a threshold.
9.4. Methods to evaluate target organ damage
Basic modalities to evaluate the severity of hyperten-
sive target organ damage in children include evalu-
ation of LVM, systolic function, and diastolic func-
tion by echocardiography, ECG, fundoscopy, and 
evaluation of renal function.
9.4.1. Evaluation of left ventricular mass
Left ventricular mass is a major criterion of target 
organ damage in hypertension. Echocardiography 
is the standard method to diagnose left ventricular 
hypertrophy, and ECG is only an additional diag-
nostic tool due to its low specificity and the need 
for age-specific interpretation (however, ECG also 
allows diagnosing arrhythmia and myocardial isch-
aemia, which is of practical importance as exercise/
sport-based non-drug therapy is the mainstay of 
the management of primary hypertension). The 
most commonly used approach to evaluate LVM 
is based on the recommendations of the American 
Society of Echocardiography and uses the Deve-
raux formula. As LVM depends on height, it is 
recommended to calculate LVM indexed for height 
in meters to the power of 2.7 according to the for-
mula suggested by DeSimone. Published reference 
values and percentiles of the LVM index calculated 
using this formula allow using this parameter in 
children over 1 year of age. A limitation of index-
ing LVM for height is the possibility to overdiag-
nose left ventricular hypertrophy in obese children 
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in comparison to indexing for fat-free body weight. 
Nevertheless, it is currently the most commonly 
used and recommended (2009 and 2016 ESH 
guidelines, Fourth Report, AAP) approach to eval-
uate LVM in children and adolescents that allows 
not only comparisons of echocardiographic find-
ings in children of varying age but also comparing 
paediatric data with the results obtained in adults. 
However, as a hypertension classification consistent 
with the adult definitions has been introduced for 
adolescents ≥ 16 years of age, it is recommended 
to evaluate left ventricular hypertrophy in this age 
group using the adult approach (see below).
The principles of evaluating left ventricular sys-
tolic and diastolic function are the same as in adults. 
When evaluating diastolic function, a higher early 
(E) to atrial (A) inflow velocity ratio (E/A) in young-
er children should be taken into account. Tissue 
Doppler imaging is increasingly commonly used for 
the evaluation of left ventricular diastolic function, 
and respective paediatric reference values have been 
published. Findings using this method may be an ad-
ditional parameter in the evaluation of target organ 
damage.
Definitions:
• left ventricular hypertrophy — LVM ≥ 95th per-
centile for age and gender;
• severe ventricular hypertrophy — LVM index 
≥ 51 g/m2.7*.
In adolescents ≥ 16 years of age, left ventricular 
hypertrophy is diagnosed when LVM is ≥ 115 g/m2 
of body surface area in boys and ≥ 95 g/m2 of body 
surface area in girls.
It is recommended to evaluate the relative left 
ventricular wall thickness (threshold value 0.42) and 
assess left ventricular geometry (normal geometry, 
concentric remodelling, concentric hypertrophy, ec-
centric hypertrophy).
*In adult studies, it has been shown that LVM 
above 51 g/m2.7 is associated with a 4-fold higher risk 
of a cardiovascular event during 5 years of follow-up. 
LVM of 51 g/m2.7 is approximately consistent with 
the 99th percentile of LVM in children and adoles-
cents.
9.4.2. Fundoscopy
The principles of fundoscopic examination in chil-
dren do not differ from those in adults. The Keith-
Wagener-Barker classification is commonly used in 
clinical practice. A simplified classification includes 
2 types of changes, benign and malignant. Benign 
changes are Keith-Wagener-Barker grade 1 and/or 
grade 2 lesions, and malignant changes are grade 
3 and/or grade 4 lesions. The simplified classifica-
tion allows initial patient selection for more or less 
intensive treatment. Computer-assisted analysis of 
the width of retinal arteries and veins is increasingly 
used for the assessment of cardiovascular event risk, 
including that of stroke in adult hypertensives but 
this method has not been yet widely adopted in chil-
dren with hypertension.
Although initial fundus evaluation is relatively 
simple, few paediatric hypertension specialists per-
form it in routine clinical practice. For this reason, 
this test is recommended as optional in the evalua-
tion of children and adolescents with asymptomatic 
hypertension. However, it is recommended in symp-
tomatic hypertension and hypertensive emergencies 
and urgencies.
9.4.3. Evaluation of renal damage
Routine methods to evaluate renal function include 
glomerular filtration rate (GFR) estimation using 
the Schwartz formula and/or serum cystatine C level 
measurements. Albuminuria is an indicator of hy-
perfiltration and/or microvascular damage. There are 
no commonly accepted reference values for albumin-
uria in children, and adult cut-off values are used in 
practice, with albuminuria above 30 mg/24 h cor-
responding to the 95th  percentile values.
Hyperuricaemia is considered an abnormality 
specific for hypertension. However, it is not clear 
whether an increased uric acid level is a primary phe-
nomenon or occurs secondarily to subclinical renal 
damage. Clinical and population studies indicate 
that in adolescents 12–17 years of age, uric acid level 
above 5.5 mg/dL is associated with a 2-fold increased 
risk of hypertension.
Non-obligatory additional tests to evaluate the 
extent of target organ damage in children and 
adolescents:
These include:
• evaluation of large artery damage [measurement 
of the intima-media thickness (IMT)];
• measurement of the pulse wave velocity (PWV).
During the last decade, multiple reports have 
been published that support using IMT and PWV 
measurements to evaluate target organ damage, and 
reference IMT and PWV values for children and 
adolescents aged 6–20 years have been reported 
(Tab. XLII and XLIII). These tests are already recom-
mended (ESH 2016) as additional tools to evaluate 
target organ damage in children with hypertension. 
In clinical practice, however, carotid IMT and PWV 
measurements are still performed only in selected 
centres. For this reason, they are recommended as 
non-obligatory additional tests pending their wide 
introduction to clinical practice.
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9.5. Principles of the differential diagnosis 
of hypertension in children and adolescents
Differential diagnosis of hypertension in children 
includes three steps (Tab. XLIV). The extent of di-
agnostic investigations depends on the severity of 
hypertension, patient’s age, and concomitant condi-
tions. Indications for more extensive investigations 
that include diagnostic steps 1 and 2 include younger 
patient’s age (before puberty; an arbitrarily chosen 
age threshold in girls and boys in Poland is 12 years), 
grade 2 hypertension, and presence of target organ 
damage or concomitant chronic conditions. Diag-
nostic step 1 includes confirmation of the diagnosis 
of hypertension, exclusion of white coat hyperten-
sion, grading the severity of hypertension, evaluation 
of target organ damage, and basic laboratory tests to 
exclude secondary hypertension. Diagnostic step 2 
includes tests that require hospital admission and is 
generally appropriate in children with grade 2 hy-
pertension and younger children with hypertension. 
Diagnostic step 3 includes highly specialized tests 
reserved for patients in whom the diagnosis has not 
been established despite completed step 1 and 2 in-
vestigations or hypertension is resistant to treatment.
Table XLII. Referential values of common carotid artery intima-media thickness (50th and 95th percentile) in millimetres
Age (years)
50th percentile [mm] 95th percentile [mm]
Boys Girls Boys Girls
6 0.37 0.36 0.44 0.43
7 0.37 0.37 0.44 0.43
8 0.37 0.37 0.44 0.44
9 0.37 0.37 0.45 0.44
10 0.38 0.37 0.45 0.44
11 0.38 0.38 0.45 0.44
12 0.38 0.38 0.46 0.44
13 0.38 0.38 0.46 0.45
14 0.39 0.38 0.47 0.46
15 0.39 0.38 0.47 0.46
16 0.40 0.39 0.48 0.46
17 0.40 0.39 0.48 0.46
18 0.40 0.39 0.48 0.47
Table XLIII. Referential values of pulse wave velocity (95th and 97th percentile) evaluated by tonometry (PulsePen; based on Reusz et al., 
Hypertension 2010) and the oscillometric method (Vicorder)
Age (years) 
PulsePen (tonometry) Vicorder (oscillometric method)
Boys  
95th percentile [m/s]
Girls  
95th percentile [m/s]
Boys  
97th percentile [m/s]
Girls  
97th percentile [m/s]
7 5.4 5.2 4.8 4.8
8 5.5 5.4 5.0 5.0
9 5.5 5.5 5.1 5.1
10 5.6 5.6 5.2 5.3
11 5.8 5.8 5.4 5.4
12 5.9 5.9 5.5 5.5
13 6.1 6.0 5.7 5.6
14 6.3 6.0 5.8 5.7
15 6.5 6.2 6.0 5.7
16 6.7 6.3 6.2 5.7
17 6.9 6.5 6.3 5.6
18 7.1 6.7
19 7.3 6.9
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The diagnosis of hypertension in children and 
adolescents should by confirmed by ABPM. Due to 
lack of reference values for younger children and the 
possibility of false positive diagnoses, only children 
above 5 years of age and/or above 120 cm in height 
should be routinely referred for ABPM. In younger 
children, the diagnosis of hypertension is based on 
office measurements, and ABPM is performed in 
individually selected cases.
In most children with hypertension, an imme-
diate institution of antihypertensive therapy is not 
necessary, which usually allows complete diagnostic 
investigations before the treatment is started. Indica-
tions for initiating antihypertensive therapy before 
completion of the differential diagnosis include high 
BP values (grade 2 hypertension with clinical symp-
toms) and/or advanced target organ damage and/ 
/or symptomatic hypertension. Except for hyperten-
sive urgencies and emergencies, if drug treatment is 
necessary before completion of the diagnostic tests, 
long-acting dihydropyridine calcium antagonists are 
preferred as this drug class has the least effect on 
laboratory test findings.
9.6. General approach to the treatment of 
hypertension
General approach to and indications for the treat-
ment of hypertension in children and adolescents are 
based on evaluation of the severity of hypertension, 
its nature (primary versus secondary), target organ 
Table XLIV. Diagnostic steps in children and adolescents with hypertension
Investigations Comments
Step 1
• Complete blood count, creatinine, sodium, potassium, 
chloride, calcium, bicarbonate, total cholesterol, triglyce-
rides, HDL and LDL cholesterol, uric acid, glucose
• Urinalysis with culture
• Daily albumin excretion or albumin/creatinine ratio in 
a spot urine sample
• Kidney and renal artery Doppler ultrasound
• ECG
• Echocardiography with evaluation of LVM and the aortic 
arch
• cIMT measurement
• Transcranial ultrasound in neonates and infants
• ABPM in children > 5 years of age
Step 1 investigations should be performed in all patients  
with the diagnosis of hypertension
cIMT measurement is optional
ABPM is currently widely available; evaluation in children  
< 6 years of age has not been validated
Step 2
• Fasting blood glucose, oral glucose tolerance test, insuli-
naemia in patients with BMI > 85th percentile
• Urinary catecholamines in younger children and all pa-
tients with grade 2 hypertension
• Plasma renin activity/renin level and aldosterone level 
in younger children and all patients with grade 2 hyper-
tension
• Urinary steroid profile or urinary 17-keto- and 17-hy-
droxysteroids in younger children and all patients with 
grade 2 hypertension
• Thyroid hormones, vitamin D3 metabolites
• Renal scintigraphy (captopril test) in younger children 
and all patients with grade 2 hypertension
Oral glucose tolerance test is recommended as mandatory in 
patients with BMI > 85th percentile. Fasting insulin allows cal-
culation of HOMA-IR, and insulin in the fasting conditions and 
at 120 minutes after glucose administration allows evaluation 
of the insulin sensitivity index. Multiple measurements during 
a 240-minute test allow calculation of areas under the glucose 
and insulin curves and are optional
Urinary steroid profile is currently recommended over previously 
used urinary 17-keto- and 17-hydroxysteroids
Measurements of thyroid hormones and vitamin D3 metabo-
lites are recommended in patients with a suspicion of specific 
pathologies
Dynamic scintigraphy is recommended to evaluate renal per-
fusion, urine excretion, relative renal function, and to estimate 
scarring (static DMSA scintigraphy is more sensitive in detect-
ing scarring but does not allow evaluation of renal perfusion)
Step 3
• Non-invasive and invasive renal artery imaging  
(CTA, MRA, invasive angiography)
• Imaging to detect adrenal lesions/paraganglioma
• Non-invasive imaging of other vascular beds  
(visceral arteries, intracranial arteries)
• Molecular testing
Step 3 investigations are performed in patients in whom the diag-
nosis has not been established despite completed step 1 and 2 
investigations and/or treatment is unsuccessful
ABPM — ambulatory blood pressure monitoring; BMI — body mass index; cIMT — common carotid artery intima-media thickness; CTA — computed tomography angiography; DMSA — dimercaptosuccinic acid; 
ECG — electrocardiogram; HDL — high-density lipoprotein; HOMA-IR — homeostatic model assessment-insulin resistance; LDL — low-density lipoprotein; LVM — left ventricular mass; MRA — magnetic resonance 
angiography
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damage, and concomitant conditions. Treatment 
monitoring and modifications based on ABPM are 
recommended (Fig. 10). Antihypertensive drug treat-
ment and its success rates depend on the aetiology of 
hypertension.
9.7. Hypertension in chronic kidney disease
Hypertension secondary to chronic kidney disease 
is the major cause of hypertension in younger chil-
dren, and the major cause of severe hypertension 
with target organ damage at all ages. Hypertension is 
present in more than 54% of children with chronic 
kidney disease, the more common, the lower GFR 
values. Hypertension is more common in children 
with chronic kidney disease due to glomerulopathy 
and occurs virtually in all in whom chronic kid-
ney disease is due to haemolytic-uraemic syndrome. 
Among dialyzed children (chronic kidney disease 
stage 5), hypertension is present in up to 80% of 
patients. The pathogenesis of hypertension in chron-
ic kidney disease includes both the renin and the 
volaemic mechanism. With decreasing GFR, sodium 
and water retention plays an increasingly important 
role in the pathogenesis of hypertension in patients 
with chronic kidney disease. Poorly controlled hy-
pertension is a major cause of cardiovascular deaths 
during renal replacement therapy. In addition to 
proteinuria, hypertension is also the major risk fac-
tor for progression of chronic kidney disease. Goals 
of hypertension treatment in children with chronic 
kidney disease include both reduction of the risk of 
future cardiovascular events and delaying chronic 
kidney disease progression. According to the Kid-
ney Disease Improving Global Outcomes (KDIGO) 
guidelines, the BP threshold for initiating antihy-
pertensive therapy is the 90th percentile for gender 
and age. In contrast, the ESH guidelines (2009 and 
2016) do not offer a clear threshold for therapy 
initiation. Based on prospective randomised stud-
ies, clinical observations, expert opinions, and the 
results of recently published metaanalyses of adult 
studies, antihypertensive therapy should be initiated 
in children with chronic kidney disease and BP val-
ues above the 90th percentile. It is recommended to 
monitor antihypertensive treatment by ABPM, and 
treatment effectiveness should be evaluated based on 
the mean 24-hour MAP. Target BP values depend on 
the severity of proteinuria. Reduction of the mean 
24-hour MAP below the 90th percentile (50–90th 
percentile range) is recommended in children with 
chronic kidney disease without proteinuria or with 
proteinuria below 0.5 g per day, and below the 50th 
percentile in children with proteinuria above 0.5 g 
per day. Of note, the 2009 and 2016 ESH guidelines 
suggested (based on the expert opinion) reducing BP 
below the 75th percentile in children with chronic 
kidney disease without proteinuria. In our opinion, 
this recommendation is not justified by the ESCAPE 
study results which are cited by ESH. In addition, 
with such target BP values, the threshold for initiat-
ing antihypertensive therapy in chronic kidney dis-
ease should be automatically reduced from the 90th 
to the 75th percentile.
First-line antihypertensive drug classes in children 
with chronic kidney disease are RAAS inhibitors: 
ACEI and ARB. This is based on the pathomecha-
nism of hypertension in chronic kidney disease and 
the published results of clinical trials and observa-
tional studies in children. Prospective multicentre 
studies showed the efficacy and safety of ACEI as 
Figure 10. Treatment of hypertension in adolescents
High normal blood 
pressure/prehypertension
Non-pharmacological 
treatment
Persisting hypertension despite 
non-drug treatment for 6–12 months
Drug treatment 
+ non-pharmacological 
treatment
Grade 2 hypertension/target 
organ damage/hypertensive 
crisis
Symptomatic
Secondary
Target organ damage
No Yes
Hypertension 
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antihypertensive and renoprotective drugs (ramipril, 
enalapril), and similar data were obtained for ARB 
(losartan) in single-centre studies. In addition, ob-
servational studies showed better BP control in 
children treated with RAAS inhibitors compared to 
other antihypertensive drug classes. These drugs are 
not recommended in patients with a very low GFR 
(< 15–20 mL/min/1.73 m2) due to a risk of signifi-
cant renal function worsening and/or hyperkalaemia. 
Dual therapy with ACEI and ARB may result in an 
additional BP-lowering effect and a reduction of pro-
teinuria. However, such treatment is currently not 
recommended if additional indications are not pres-
ent (antiproteinuric effect) due to concerns regard-
ing the safety of such combined treatment. Renin 
inhibitors were tested in clinical studies in children 
but their renoprotective effect was not evaluated and 
these drugs continue to be not licensed for use in 
children.
Achieving target BP in patients with chronic kid-
ney disease usually requires multiple antihypertensive 
drugs. Individualization of further drug treatment 
depending on the clinical scenario is recommended 
in children. Beta-blockers are the recommended 
second-line drugs in children with chronic kidney 
disease due to their additional effect on the RAAS, 
antiadrenergic effect, and a reduction of proteinuria. 
Diuretics are recommended for fluid retention which 
is usually seen in children with GFR below 40 mL/
min/1.73 m2. In children with large proteinuria or 
low GFR, often the diuretic dose has to be increased 
for an adequate therapeutic effect. Thiazide/thiazide-
-like diuretics retain their effectiveness only in pa-
tients with GFR above 30–40 mL/min/1.73 m2. Di-
hydropyridine calcium antagonists, previously used 
as first-line drugs in children with chronic kidney 
disease, are currently used as further choice drugs 
due to the fact that they increase hyperfiltration and 
proteinuria. However, this negative effect is absent or 
reduced in combination with RAAS inhibitors.
9.7.1. Hypertension in patients undergoing 
dialysis therapy
Hypertension is found in 55–79% of children with 
chronic kidney disease who require renal replace-
ment therapy, including 56–79% treated with hae-
modialysis, 54–75% treated with peritoneal dialysis 
(in Poland 56% and 54%, respectively), and ap-
proximately 66% of patients after kidney transplan-
tation. Of note, about 20% of these patients with 
hypertension remain untreated, and among those 
treated, hypertension is not controlled in nearly 75% 
of children. As BP measurements performed in dialy-
sis units (before and after haemodialysis) show less 
correlation with left ventricular hypertrophy com-
pared to 24-hour ABPM in the interdialytic period, 
the diagnosis of hypertension in children on chronic 
dialysis treatment should be based on ABPM in the 
interdialytic period. The main risk factors for hyper-
tension in children on chronic dialysis treatment are 
hypervolaemia and excessive salt intake. Other risk 
factors include young age (< 6 years), black race, 
female gender, acquired underlying kidney disease, 
anaemia in patients treated with haemodialysis, and 
duration of dialysis therapy, with a lower proportion 
of hypertension among patients undergoing dialysis 
therapy for a longer time. The most important ele-
ment in the prevention and treatment of hyperten-
sion in children undergoing dialysis therapy is proper 
assessment of the volume status and achieving so 
called dry mass. It is believed that safe increase in 
body weight between dialysis sessions in children 
should not exceed 3% of the body dry mass. In 
paediatric patients undergoing peritoneal dialysis, 
the main cause of hypervolaemia is occult overhy-
dration associated with uraemic cachexia. In these 
patients, residual diuresis plays a major role, as the 
higher is the latter, the lower BP increase related to 
hypervolaemia.
According to the 2005 National Kidney Founda-
tion Kidney Disease Outcomes Quality Initiative 
(NKF KDOQI) guidelines, BP values below the 
95th  percentile for gender, age, and height should 
be aimed for in children requiring chronic renal re-
placement therapy. Normal body dry mass should be 
achieved by intensification of dialysis therapy, with 
session duration increased to 5–8 hours, perform-
ing 4–6 procedures per week, and periodic use of 
haemodiafiltration and/or nocturnal dialysis. In pa-
tients undergoing peritoneal dialysis, increased ultra-
filtration can be achieved by using higher osmolality 
dialysis fluids or icodextrin-containing fluids. Dihy-
dropirydine calcium antagonists, ACEI, and ARB are 
used for drug therapy. There are no clear guidelines 
regarding drug choice but attention should be paid 
to hyperkalaemia that accompanies use of the two 
latter drug classes.
9.8. Renovascular hypertension
Renovascular hypertension is among the major 
causes of severe hypertension in children and adoles-
cents. The most common cause of renovascular hy-
pertension in this age group is FMD but in 20–40% 
of cases, renovascular hypertension is a complica-
tion of other conditions (syndromic renovascular 
hypertension), including neurofibromatosis type 1 
(> 15%). Renovascular hypertension may also be 
caused by a congenital or acquired (e.g., transplant 
arterial hypertension 2019, vol. 23, no. 4
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renal artery stenosis) stenosis of the main renal ar-
tery or additional renal arteries and/or segmental 
branches.
9.8.1. Investigations for and the diagnosis 
of renovascular hypertension
The diagnosis of renovascular hypertension is based 
on a finding of a haemodynamically significant ste-
nosis of one or both renal arteries (Fig. 11). Invasive 
angiography, often with selective renal artery cath-
eterization, is still considered a reference method 
but should be performed only directly prior to in-
tervention and during the same procedure if percu-
taneous treatment is planned based on the results of 
non-invasive imaging. Of note, the sensitivity and 
specificity of non-invasive imaging studies in chil-
dren and adolescents with renovascular hypertension, 
such as Doppler ultrasonography (73% and 83%, 
respectively), MRA (80% and 62%) and CTA (93% 
and 81%), are significantly lower than those of con-
ventional invasive angiography used to confirm the 
diagnosis.
Routine evaluation of renal vein renin activity 
or level is not recommended. This test may be per-
formed in case of diagnostic uncertainties.
In the diagnostic algorithm for renovascular hy-
pertension, scintigraphy is not recommended neither 
in the AAP guidelines nor in the adult guidelines, 
including the PTNT guidelines. A similar opinion is 
shared by the authors of the present guidelines but 
it should be noted (an expert opinion) that assess-
ment of kidney excretory function may help guide 
a decision regarding surgical treatment in difficult 
cases (small children, percutaneous intervention not 
feasible), and after invasive treatment (percutane-
ous intervention/surgery) it allows evaluation of the 
treatment outcomes and is an additional criterion 
for the diagnosis of hypertensive nephropathy in 
a kidney with normal renal artery exposed to high 
BP values before treatment.
9.8.2. Treatment of renovascular hypertension
The ultimate and causative therapy of renovascu-
lar hypertension is an interventional treatment that 
Figure 11. Diagnosis and treatment in children with renovascular hypertension. CNS — central nervous system; CTA — computed tomo-
graphy angiography; MRA — magnetic resonance angiography; PTRA — percutaneous transluminal renal angioplasty
Child with grade 2 hypertension and/or a small child with grade 1 hypertension 
and/or symptoms/intermediate phenotype suggesting secondary hypertension
Doppler ultrasound, renal scintigraphy, possibly captopril scintigraphy
Abnormal result suggesting 
renovascular hypertension
CTA (kidneys, renal arteries, 
aorta and possibly other 
vascular beds, e.g. CNS)
Invasive angiography with an attempt of PTRA 
— based on CTA ndings
Surgical treatment
Cure/repeat 
angioplasty/follow-up
Periodic evaluation of treatment effects: 
Doppler ultrasound, renal scintigraphy, 
possibly CTA/MRA
Normal result
Treatment according to 
intermediate phenotype
No effect
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eliminates the underlying cause of hypertension. Al-
though drug treatment allows at least partial BP 
control, it does not cure the patient. In patients 
with Takayasu disease, immunosuppressive treatment 
should be considered causative therapy, and antihy-
pertensive treatment, including invasive procedures, 
is targeted at the disease complications.
Drug treatment of renovascular hypertension de-
pends on whether unilateral or bilateral renal artery 
stenosis is present (Tab. XLV).
9.8.2.1. Interventional treatment of renovascular 
hypertension
Interventional treatment of renovascular hypertension 
includes percutaneous transluminal renal angioplasty 
(PTRA) and surgical revascularization. PTRA may be 
successfully undertaken by balloon angioplasty with 
or without stenting. PTRA is the initial step of the 
interventional treatment and it should it be attempted 
during invasive renal angiography. Complications of 
PTRA include mechanical vessel wall damage with 
formation of a pseudoaneurysm, thrombosis, arte-
rial spasm, arterial wall laceration with bleeding, and 
entrapment of a balloon catheter within the vessel 
lumen. Some complications may require immediate 
surgical treatment, and thus both invasive renal an-
giography and PTRA should be performed in expe-
rienced paediatric centres with vascular surgical team 
backup. Local administration of an arterial smooth 
muscle relaxant should be always possible throughout 
the PTRA procedure. Drugs administered locally to 
relieve arterial spasm during PTRA include nifedip-
ine, nitroglycerin, and sodium nitroprusside. Accord-
ing to experts’ recommendations, prophylactic doses 
of low-molecular-weight heparin should be given for 
1–7 days after the procedure in all cases of renal artery 
catheterization with PTRA, followed by administra-
tion of ASA at 1 mg/kg/day for 3–6 months.
Experience with stenting in renovascular hyper-
tension in children and adolescents is relatively lim-
ited. Due to ongoing growth, stents mounted on 
balloon catheters that can be redilated later are rec-
ommended. If it is possible to implant a stent with 
a diameter corresponding to the size of the renal 
artery in an adult person, implantation of a self-
expandable stent is an alternative option.
Surgical treatment (revascularization or nephrec-
tomy) is the ultimate approach to the treatment of 
renovascular hypertension. Surgical revascularization 
is indicated if drug therapy and PTRA were unsuc-
cessful, and nephrectomy is indicated for unilateral 
renal artery stenosis with severely impaired func-
tion of the ischemic kidney. Nephrectomy is consid-
ered appropriate if the ischemic kidney is reduced in 
size and its relative function has decreased to below 
10–15%. In children and adolescents in whom reno-
vascular hypertension is associated with an involve-
ment of visceral vessels and/or midaortic syndrome, 
the therapeutic approach must be planned individu-
ally and mostly commonly involves staged proce-
dures, taking into consideration their possible extent, 
type and sequence, including renal revascularization.
Major surgical techniques used for renal revascu-
larization in adolescents include repair using a pros-
thetic or autologous patch, and kidney autotrans-
plantation following excision of the stenosed arterial 
segment.
9.9. Hypertension in children after surgical 
treatment of coarctation of the aorta
Hypertension is an invariable and major symptom 
of congenital coarctation of the aorta. Following in-
terventional treatment that resulted in a correction 
of the anatomical stenosis, hypertension persists or 
develops after a period of normotension in about 
32.5% (25–68%) of patients. In a large proportion 
of patients, exercise-induced hypertension may be 
diagnosed based on an exercise test.
9.9.1. Treatment of hypertension in children 
after surgical treatment of coarctation of the aorta
Paediatric studies showed efficacy of ACEI (ramipril), 
ARB (candesartan), and b-blockers (metoprolol). 
AHA recommends ARB or ACEI and b-blockers 
as first-line drugs. In patients with coarctation of 
the aorta, routine annual ABPM and an exercise 
test every 2 years are recommended by the experts. 
Abnormal results of these tests are an indication 
for drug therapy and possible diagnostic investiga-
tions for recoarctation. According to both AHA and 
ESC guidelines, assessment of postprocedural aortic 
anatomy, including that of the aortic arch, as factors 
affecting development of recoarctation and severity 
of hypertension, requires repeated imaging studies 
(echocardiography, CTA, or MRA depending on the 
Table XLV. Drug treatment of renovascular hypertension.
Unilateral renal artery stenosis Bilateral renal artery stenosis
ACEI/ARB (use in caution;  
  usually in cases of lack  
  of effect of other drugs)
Dihydropyridine calcium  
  antagonists 
b-blockers
a-blockers 
Centrally acting imidazoline  
  agonists 
Diuretics
Dihydropyridine calcium  
  antagonists
b-blockers
a-blockers
Centrally acting imidazoline  
  agonists
ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers
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patient’s age), usually every several years. In patients 
with coarctation of the aorta and concomitant bicus-
pid aortic valve, this surveillance must also include 
the anatomy and (dys)function of aortic valve, and 
the degree of ascending aortic dilatation. In these 
patients, treatment of hypertension should be par-
ticularly aggressive.
9.10. Monogenic hypertension
The diagnosis of monogenic hypertension is based 
on the finding of a typical intermediate phenotype, 
which is often possible already during step 1 and 
2 investigations. In some cases, a family history 
of hypertension associated with a typical pheno-
type or resistance to treatment may be ascertained 
(Tab. XLVI). The diagnosis of a specific form usu-
ally allows treatment directed at major abnormalities 
leading to hypertension. The evaluation and treat-
ment of these forms of hypertension should be un-
dertaken in tertiary care centres where the molecular 
diagnosis is available.
9.11. Primary hypertension
Primary hypertension is the major cause of hyperten-
sion in children above 12 years of age, accounting for 
about 50% of all cases of hypertension in the devel-
opmental period. Recently, it has been increasingly 
diagnosed also in younger children, including those 
below 6 years of age, and is associated with obesity. 
The predominant intermediate phenotype of primary 
hypertension is abnormal body composition with vis-
ceral obesity, abnormal muscle-to-adipose tissue pro-
portion, and metabolic disturbances typical for meta-
bolic syndrome (Tab. XLVII). In addition, a trend for 
higher uric acid level is typical for essential hyperten-
sion. The risk of target organ damage is related to the 
degree of metabolic abnormalities and the amount of 
visceral fat as evaluated by waist circumference.
9.11.1. Management of primary hypertension
Non-drug therapy including both dietary modifi-
cations and physical activity (moderate- to high-
intensity exercise for 60 to 90 minutes daily) is of 
major importance in the management of primary 
hypertension. There are no contraindications to par-
ticipate in specific types of sport/exercise. The dietary 
management is the same as for the prevention and 
treatment of obesity. In addition to limitations re-
garding the size, composition, and energy value of 
meals, a significant reduction in salt intake is also 
important. In practice, this calls for elimination of 
adding salt to foods.
Drug therapy should be considered in children 
with grade 1 essential hypertension in whom BP 
was not adequately lowered despite 6–12 months of 
non-drug therapy. Drug therapy is indicated in chil-
dren with grade 2 hypertension and/or target organ 
damage. Due to concomitant metabolic disturbances 
and the mechanism of action (increase in peripheral 
vascular resistance), b-blockers and diuretics are not 
recommended as first- and second-line drugs, and 
the preferred drug classes are ACEI, ARB, and di-
hydropyridine calcium antagonists. In post-pubertal 
women who do not use contraception, new genera-
tion b-blockers with vasodilatatory properties may be 
recommended, as these drugs do not induce adverse 
metabolic effects and do not increase peripheral vas-
cular resistance, as well as dihydropyridine calcium 
antagonists. Due to the fact that the risk of target or-
gan damage is associated with metabolic disturbances 
and visceral obesity, it is recommended to include 
regular anthropometric measurements (body weight, 
waist circumference) in addition to evaluation of BP 
values and target organ damage when monitoring 
treatment effects.
9.12. Hypertension in children with diabetes
Diabetes type 1 is currently present in about 205,000 
individuals in Poland, including about 20,000 chil-
dren and adolescents. A four-fold increase in the 
incidence of diabetes type 1 has been noted over the 
last 25 years. With increasing rates of overweight 
and obesity in the Polish population, the number of 
children with diabetes type 2 also increases.
 Based on few studies that used the generally 
accepted paediatric definition for the diagnosis, the 
prevalence of hypertension among children with dia-
betes type 1 has been estimated at 4–7%, while hy-
pertension is present in as many as 23–40% of young 
patients with diabetes type 2. Consistent with the 
pathogenesis of diabetes type 2, a higher severity of 
metabolic disturbances and the metabolic syndrome 
is also seen in this patient group. Although hyperten-
sion is usually seen in patients with diabetes type 2, 
its occurrence in children and adolescents with dia-
betes type 1 is an increasingly common clinical prob-
lem. Hypertension is associated with an increased 
risk of micro- and macrovascular complications, car-
diovascular disease and diabetic nephropathy which 
are major causes of morbidity and mortality among 
patients with diabetes type 1 and 2.
9.12.1. Pathogenesis of hypertension in children 
with diabetes
The pathogenesis of hypertension in children with 
diabetes type 1 is not been entirely clear. Comparison 
of the clinical presentation in children with essential 
hypertension and those with diabetes type 1 and hy-
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pertension suggests a role of common pathogenetic 
mechanisms, such as overweight and obesity, ab-
normal distribution of fat tissue, and related insulin 
resistance. Other factors are worse diabetes control 
and use of higher insulin doses. Similarly to the gen-
eral population, a significant increase in the rate of 
hypertension since puberty is seen among children 
with diabetes type 1. Patients with diabetes type 1 
are also characterized by an abnormal diurnal BP 
pattern, including non-dipping and rapid and sig-
nificant morning BP surge. An association between 
elevated BP and an abnormal diurnal BP pattern 
with early markers of kidney damage suggests a role 
of both renal mechanisms and central BP regulation. 
Metabolic disturbances due to chronic hyperglycae-
mia, leading to arteriosclerosis and increased arterial 
stiffness, also contribute to the development of ab-
normal BP control in diabetic patients.
Although renal failure due to diabetic nephropa-
thy usually develops only after many years of disease, 
early stages of diabetic nephropathy, characterized 
by increased urinary albumin excretion, are seen also 
in the paediatric population. Kidney damage due to 
diabetes type 1 in adolescents is directly associated 
with elevated BP values, and effective BP-lowering 
treatment reduces progression of this complication.
Among children and adolescents with diabetes 
type 2, hypertension is present at the time of diabetes 
diagnosis in 12–25% of patients and is associated 
with disturbances related to insulin resistance and 
associated abdominal obesity. In addition, patients 
with diabetes type 2 present more commonly with 
atherogenic dyslipidaemia leading to early increased 
arterial stiffness, and patients with severe obesity 
develop renal dysfunction already prior to the devel-
opment of overt diabetes type 2. In some patients, 
elevated urinary albumin excretion is present at the 
time of diabetes diagnosis. Concomitant presence 
of hypertension and other features of metabolic 
syndrome predisposes to more frequent and earlier 
development of cardiovascular disease and nephropa-
thy compared to diabetes type 1. For this reason, 
patients with diabetes type 2 require comprehensive 
treatment of all disturbances related to metabolic 
syndrome.
9.12.2. Evaluation of hypertension in children 
with diabetes
In children and adolescents with diabetes, BP mea-
surements should be performed at each visit, and at 
least twice a year in children below 7 years of age. 
In adolescents above 12 years of age with diabetes 
type, abnormal BP is defined as values above the 95th 
percentile or > 130/80 mm Hg regardless of the 95th 
percentile value. Performance of a 24-hour ABPM is 
recommended to confirm hypertension.
Due to an increased risk of cardiovascular disease 
in diabetic children, it is recommended to lower BP 
at least to the 90th percentile for age, gender, and 
height, or to ≤ 120/80 mm Hg regardless of age.
Blood pressure lowering leads to regression of tar-
get organ damage but too intensive treatment with 
DBP reduction below 60 mm Hg may impair coro-
nary flow.
Investigations for secondary hypertension should 
be performed using the approach discussed above.
9.12.3. Management of hypertension in patients 
with diabetes
The management of hypertension in young patients 
with diabetes should include lifestyle modifications, 
good metabolic control of diabetes, and drug ther-
apy. A major role is played by non-drug therapy 
which included normalization of body weight (BMI 
below the 90th percentile for gender and age), regu-
lar physical activity (moderate- to high-intensity 
exercise for > 1 hour daily), and low-sodium diet 
(Tab. XLVIII).
For drug therapy, the recommended antihyper-
tensive drug classes in children and adolescents with 
hypertension and diabetes are ACEI, or ARB in case 
of ACEI intolerance. Antihypertensive therapy in 
children with diabetes is also a nephroprotective 
Table XLVII. Definitions of metabolic syndrome in children accor-
ding to the International Diabetes Federation, 2007
Age Criteria
 < 10 years Metabolic syndrome should not be diagnosed. 
Extended diagnostic investigations are indicated 
in risk groups
10–15 years 
(< 16 years)
Waist circumference ≥ 90th percentile or ≥ cut-off 
point for adult patients + 2 or more from the fol-
lowing criteria:
— serum triglycerides ≥ 150 mg/dL
— serum HDL cholesterol < 40 mg/dL
— SBP > 90th percentile
— fasting blood glucose ≥ 100 mg/dL or type 2 
diabetes
 > 16 years Criteria as in adults:
Waist circumference ≥ 94 cm in boys and 80 cm 
in girls
+ 2 or more from the following criteria:
— serum triglycerides ≥ 150 mg/dL
— serum HDL cholesterol < 40 mg/dL in boys  
and < 50 mg/dL in girls
— SBP ≥ 130 mm Hg and/or DBP ≥ 85 mm Hg 
or antihypertensive drug treatment
— fasting blood glucose ≥ 100 mg/dL or type 2 
diabetes
DBP — diastolic blood pressure; HDL — high-density lipoprotein; SBP — systolic blood pressure
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treatment and is based on similar principles. Ef-
fective drug therapy in patients with diabetic ne-
phropathy delays development of end-stage renal 
failure. ACEI treatment in adolescents is continued 
for many years, which may lead to multiple adverse 
effects, such as cough, hyperkalaemia, headaches, 
impotence, and a risk of pseudoallergic reactions. 
Possible severe foetal complications should be also 
borne in mind, which is a potential problem when 
treating adolescent girls.
In one third of patients with diabetes type 2, 
monotherapy using ACEI or ARB is ineffective. 
These patients required combined drug therapy, and 
the second-line drugs are dihydropyridine calcium 
antagonists followed by vasodilating b-blockers and 
possible thiazide-type diuretics.
9.13. Hypertension with emergent and urgent 
indications for treatment
In the developmental period, hypertensive emergen-
cies are virtually always caused by secondary hyper-
tension, including due to acute kidney disease (acute 
glomerulonephritis, haemolytic-uraemic syndrome). 
Hypertensive urgencies related to an acute BP in-
crease are also seen in children with primary hyper-
tension. The management of hypertensive emergen-
cies and urgencies has been evaluated in case reports 
and case series but not in controlled clinical studies, 
and recommendations presented in the guidelines 
(ESH 2009 and 2016, Fourth Report, AAP 2017) 
are based on expert opinions (Fig. 12). It is rec-
ommended to treat hypertensive emergencies in an 
intensive care unit, with intravenous line access and 
ECG, BP, respiratory function (pulse oximetry), and 
fluid balance monitoring. BP should be measured ev-
ery 15 minutes until it is reduced by 30% compared 
to the baseline. Biochemical blood testing including 
renal function, electrolytes, and venous blood gases 
is recommended in all patients with hypertensive 
urgencies and emergencies, and if the aetiology of 
hypertension is not known, an initial differential 
diagnosis should also be performed including re-
nal ultrasound with Doppler evaluation of the re-
nal arteries and echocardiography to evaluate LVM. 
During subsequent hours of treatment, BP may be 
measured every 30–60 minutes depending on the 
clinical condition of the patient. The general ap-
Table XLVIII. Treatment of hypertension in children with diabetes
Threshold values Treatment
BP > 90th percentile for age, 
gender, and height 
Lifestyle changes*
BP > 90th percentile for age, 
gender, and height despite life-
style changes 
+ ACEI/ARB
BP > 95th percentile for age, 
gender, and height
Lifestyle changes* + ACEI/ARB
*Body weight reduction to normal values (body mass index < 90th percentile) and physical activity 
> 1 hour per day. It is recommended to monitor treatment effects using home blood pressure measu-
rements and ambulatory blood pressure monitoring, including evaluation of nocturnal blood pressure 
fall (dipping). ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; 
BP — blood pressure
Figure 12. Management of an acute blood pressure rise in children and adolescents
Acute blood pressure rise
Acute target organ damage 
and/or organ failure 
and/or life-threatening 
complications
No acute target organ 
damage/life-threatening 
complications/organ failure
Intravenous antihypertensive drugs:
— labetalol + hydralazine/sodium nitroprusside/
     /nitroglycerin/nicardipine/urapidil
— basic differential diagnosis
— gradual blood pressure lowering
— treatment of complications
— oral drugs following improvement of the overall 
     condition of the patient and/or signicant 
     blood pressure lowering
Use of oral drugs is usually possible.
Intravenous treatment in case 
if intolerance of/inability 
to use oral drugs
Hypertensive emergency Hypertensive urgency
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proach to the treatment of a hypertensive emergency 
in children and adolescents is based on gradual, con-
trolled BP reduction. It is recommended to lower 
BP by 25–30% of the overall target BP reduction 
within 6–8 hours and by another 30% within the 
next 24–36 hours. Normal BP values (< 90th to 95th 
percentile) should be reached within 72–96 hours. 
Intravenous medications are used for the treatment 
of hypertensive emergencies, with the choice of the 
drug based on the aetiology of hypertension. In hy-
pertensive emergencies, administration of an intrave-
nous b-blocker (labetalol, esmolol) and a peripheral 
vasodilating agent (hydralazine, sodium nitroprus-
side, or nitroglycerin) is recommended. Due to fluid 
retention caused by peripheral vasodilation during 
prolonged therapy, an addition of a diuretic is also 
recommended. Oral treatment is initiated upon im-
provement of the general clinical condition of the 
patient. In hypertensive crisis due to acute or chronic 
kidney disease (patients on dialysis therapy), volume 
control and removal of excess fluid by dialysis, or 
using diuretics in patients with preserved glomeru-
lar filtration, is of major importance. Addition of 
a RAAS inhibitor is recommended in hypertensive 
emergencies due to microangiopathy.
In hypertensive urgencies, oral treatment is usually 
possible. BP should be lowered by 30% within the 
first 6 hours, and target BP values should be gradually 
reached during the next 36–48 hours. The approach 
to the management of an acute BP increase is shown 
in Figure 12, and dosing of the drugs used in hyper-
tensive emergencies and urgencies, along with their 
adverse effects and contraindications, is summarized 
in Tables XLIX and L. In children with hypertensive 
urgencies and those with an acute BP increase who 
may be treated with oral medications, rapidly acting 
drugs are recommended, followed by institution of 
long-term antihypertensive therapy (Tab. LI).
Other selected forms of hypertension are listed in 
Table LII.
9.14. Neonatal hypertension
The incidence of hypertension in neonates is about 
0.2–0.3%. However, it is much higher (0.81–9%) 
Table XLIX. Antihypertensive drugs used in hypertensive emergencies
Antihypertensive 
drug Dosage Comments
Labetalol
Bolus: 0.2–1 μg/kg per dose, 
maximum 40 mg/kg per dose
Infusion: 0.25–3 μg/kg/hour
Contraindications: asthma, heart failure, diabetes
May result in hyperkalaemia and hypoglycaemia
Does not induce reflex tachycardia
Onset of action: 5–10 minutes
Phentolamine Bolus: 0.05–0.1 mg/kg per dose, maximum 5 mg per dose
May result in tachycardia
Drug of choice in an adrenergic crisis
Onset of action: 1–2 minutes
Furosemide Bolus: 0.5–5 mg/kg per dose
Need to monitor potassium level (may cause hypokalaemia), useful in hyperten-
sion due to hypervolaemia
Onset of action: 5–10 minutes
Hydralazine Bolus: 0.2–0.6 μg/kg, maximum 20 mg per dose IV or IM
Often reflex tachycardia, fluid retention, headaches. Intravenous boluses should 
be given every 4 hours. Need for concurrent furosemide administration
Onset of action: 10–20 minutes
Sodium  
nitroprusside Infusion: 0.5–8 μg/kg/min
Risk of cyanide poisoning if long-term use or concomitant renal or hepatic failure
Need to monitor cyanide levels during long-term use (> 48 hours)
Onset of action: 1–2 minutes
Nitroglycerin Infusion: 0.1–2 μg/kg/min
May result in methaemoglobinaemia; vasodilating effect mainly in the venous 
bed — effective in heart failure, limited effectiveness in children
Onset of action: 2–5 minutes
Esmolol Infusion: 100–500 μg/kg/min,  maximum 1000 μg/kg/min
May result in bradycardia
Contraindications: asthma, heart failure
Very short duration of action
Onset of action: 1–2 minutes
Nicardipine Bolus: 30 μg/kg, maximum 2 mg per doseInfusion: 0.5–4 μg/kg/min
May induce reflex tachycardia
Onset of action: 5–10 minutes
Enalaprilat Bolus: 5–10 μg/kg per dose, maximum 1.2 mg per dose
May result in long-lasting hypotension, hyperkalaemia or acute renal failure
Limited indications
Onset of action: 15–30 minutes
IM — intramuscular; IV — intravenous
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Table L. Oral antihypertensive drugs used in hypertensive urgencies
Antihypertensive drug Dosage Comments
Captopril 0.1–0.2 mg/kg per dose,  maximum 6 mg/kg/day
Need to monitor potassium and creatinine level
Onset of action: 10–20 minutes
Clonidine 2–5 μg/kg per dose,  maximum 10 μg/kg per dose
Adverse effects: dry mouth, sedation
Onset of action: 30–60 minutes
Amlodipine 0.06–0.3 mg/kg per dose,  maximum 5–10 mg per dose
Adverse effects: dizziness, reflex tachycardia
Onset of action: 1–2 hours
Doxazosin* 1 mg per dose,  maximum 4 mg/day
Adverse effects: dizziness, orthostatic hypotension
Onset of action: 1–2 hours
Prazosin* 0.05–1 mg/kg/day in 3 doses, maximum 0.5 mg/kg/day
Adverse effects: dizziness, nausea, orthostatic hypotension
Onset of action: 1–2 hours
Propranolol*
1 mg/kg/day in 2–3 doses, maxi-
mum 4 mg/kg/day  
up to 640 mg/day
Contraindications: asthma, bradycardia, cardiac arrhythmia, diabetes
Adverse effects: bradycardia, bronchospasm, hypotension, Raynaud phenomenon
Onset of action: 1–2 hours
*Drugs recommended in adrenergic hypertension (phaeochromocytoma/paraganglioma/neuroblastoma). In such cases, blood pressure should be first reduced using a-blockers (doxazosin, prazosin), followed by initia-
tion of a b-blocker (propranolol)
Table LI. Recommended doses of oral antihypertensive drugs in children
Drug class Drug Initial dose Number of daily doses Maximum dose
Aldosterone  
antagonists
Eplerenone 25–50 mg/day 1–2 100 mg/day
Spironolactone 1 mg/kg/day 1–2 3.3 mg/kg/day  up to 100 mg/day
Angiotensin-converting 
enzyme inhibitors
Benazepril 0.2 mg/kg/day  up to 10 mg/day 1 
0.6 mg/kg/day  
up to 40 mg/day
Captopril 0.3–0.5 mg/kg per dose 2–3 6 mg/kg/day  up to 450 mg/day
Enalapril 0.08–0.6 mg/kg/day 1–2 40 mg/day
Fosinopril 0.1–0.6 mg/kg/day  or 5–10 mg/day 1 40 mg/day
Lisinopril 0.08–0.6 mg/kg/day  up to 5 mg/day 1 
0.6 mg/kg/day  
up to 40 mg/day
Quinapril 5–10 mg/day 1 80 mg/day
Ramipril 2.5–6.0 mg/day (6 mg/m2/day) 1 20 mg/day
Angiotensin receptor 
blockers
Candesartan 0.16–0.5 mg/kg/day  up to 4 mg/day 1 32 mg/day
Irbesartan 75–150 mg/day 1 300 mg/day
Losartan 0.75 mg/kg/day  up to 50 mg/day 1 
1.4 mg/kg/day  
up to 100 mg/day
Valsartan 0.4 mg/kg/day 1 40–80 mg/day
Olmesartan 2.5 mg/day 1 40 mg/day
Renin inhibitors Aliskiren 2 mg/kg/day 1 6 mg/kg/day  up to 600 mg/day
a- and b-blockers
Labetalol 1–3 mg/kg/day 2 10–12 mg/kg/day  up to 1.2 g/day
Carvedilol 0.1 mg/kg/ per dose up to 12.5 mg per dose 2 
0.5 mg/kg per dose  
up to 50 mg/day
b-blockers
Atenolol 0.5–1 mg/kg/day 1–2 2 mg/kg/day  up to 100 mg/day
Bisoprolol/ 
/hydrochlorothiazide
0.04 mg/kg/day
up to 2.5/6.25 mg/day 1 10/6.25 mg/day
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among prematurely born infants and with the pres-
ence of additional risk factors (umbilical vessel cath-
eterization, patent ductus arteriosus, intraventricular 
haemorrhage) and concomitant conditions (40% in 
neonates and infants with chronic bronchopulmo-
nary disease). Neonatal hypertension is generally of 
a secondary nature, related mainly to renal pathol-
ogy, most commonly renovascular disease, but iatro-
genic factors are also of major importance.
Despite multiple data on normal BP values in 
neonates depending on specific measurement tech-
niques, the definition of hypertension is still based 
on the percentile values reported in the 1987 Re-
port of the Second Task Force on Blood Pressure 
Control in Children and derived from BP mea-
surements using a mercury sphygmomanometer 
(Tab. LIII). According to the 1987 Report of the 
Second Task Force, hypertension may be diagnosed 
in neonates when SBP values above the 95th per-
centile for chronological age are found on three oc-
casions. Despite numerous methodological limita-
tions and the fact that BP is currently nearly always 
measured by the oscillometric method, reference BP 
values given in the 1987 Report of the Second Task 
Table LI. Recommended doses of oral antihypertensive drugs in children
Drug class Drug Initial dose Number of daily doses Maximum dose
b-blockers
Metoprolol 0.5–1.0 mg/kg/day 1–2 2 mg/kg/day 
Propranolol 1 mg/kg/day 2–3 4 mg/kg/day  up to 640 mg/day
Calcium antagonists
Amlodipine 0.06–0.3 mg/kg/day 1 5–10 mg/day
Felodipine 2.5 mg/day 1 10 mg/day
Isradipine 0.05–0.15 mg/kg per dose 3–4 0.8 mg/kg/day  up to 20 mg/day
Nifedipine (slow release) 0.25–0.5 mg/kg/day 1–2 3 mg/kg/day  up to 120 mg/day
Central a-agonists
Clonidine 2–5 μg/kg per dose 2 10 μg/kg/day
Methyldopa 5 mg/kg/day 2–3 40 mg/kg/day up to 3 g/day
Diuretics
Amiloride 0.4–0.6 mg/kg/day 1 20 mg/day
Chlorthalidone 0.3 mg/kg/day 1 2 mg/kg/day  up to 50 mg/day
Furosemide 0.5–2.0 mg/kg per dose 1–2 6 mg/kg/day
Hydrochlothiazide 0.5–1 mg/kg/day 1 3 mg/kg/day
Triamterene 1–2 mg/kg/day 2 3–4 mg/kg/day  up to 300 mg/day
a-blockers
Doxazosin 1 mg/day 1 4 mg/day
Prazosin 0.05–0.1 mg/kg/day 3 0.5 mg/kg/day
Terazosin 1 mg/day 1 20 mg/day
Vasodilators Hydralazine 0.75 mg/kg per dose 4 7.5 mg/kg/day  up to 200 mg/day
Minoxidil 0.2 mg/kg per dose 1–3 50–100 mg/day
Force are practical and easy to use. Table LIV shows 
a compilation of previous reference BP values that 
summarizes the 95th and 99th SBP, DBP, and MAP 
percentiles in 2-week-old neonates in relation to 
gestational age at birth. 
Due to high rates of unreliable findings, including 
false positive results (up to 41% in children below 12 
months of age), and resulting exposure to unneces-
sary investigations and treatment, BP measurement 
in healthy neonates is not recommended. BP mea-
surements and investigations for hypertension are 
indicated in neonates born prematurely, those with 
concomitant congenital disease or other conditions 
associated with hypertension, and in neonates who 
require hospital admission. It is recommended to 
perform BP measurements in appropriate conditions 
and using the technique described in Table LV. Aus-
cultatory technique should not be used in newborns, 
neonates and small children due to technical difficul-
ties and more common white coat effect compared to 
automatic, oscillometric measurements. Automatic 
BP measurements using the oscillometric method are 
prone to an erroneous finding of elevated BP values 
at the first measurement. If BP measurements are 
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indicated in these age groups and the result of the 
initial measurement is abnormal, it is recommended 
to perform multiple repeated automated measure-
ments at short intervals.
The approach to the differential diagnosis of hy-
pertension and evaluation of target organ damage 
in neonates does not differ from that in older age 
groups (Tab. LVI).
Kidney  
disease
Glomerulonephritis
Interstitial nephritis
Kidney cystic disease
Urinary tract defects
Hydronephrosis
Radiation nephropathy
Renovascular (including vasculitis)
Renin-producing tumours
Obstructive lesions (renal stones, tumours, sub-
pelvic stenosis)
Diabetic nephropathy
Hypertension after kidney transplantation
Endocrine dis-
ease
Primary hyperaldosteronism
Mineralocorticoid metabolism disturbances
Congenital adrenal hyperplasia
Cushing syndrome
Phaeochromocytoma
Hyperparathyroidism
Acromegaly
Hyperthyroidism
Hypothyroidism
Carcinoid syndrome
Cardiovascular 
disease
Coarctation of the aorta
Aortic regurgitation
Abdominal aortic syndrome
Haematologic 
disease
Anaemia
Polycytaemia
Neurologic 
disease
Porphyrias
Vegetative neuropathy
Increased intracranial pressure
Subcapsular hematoma
Tetraplegia
Guillain-Barré syndrome
Brain trauma
Brain tumour
Malignancies
Wilms’ tumour
Mesoblastic nephroma
Neuroblastoma
CNS malignancies
Acute stress
Burns
Hypoglycaemia
Hypoxia
Perioperative period
Psychogenic hyperventilation
Abstinence in alcohol- and psychoactive sub-
stance-addicted individuals
Gestational 
hypertension
Preeclampsia
Eclampsia
Reduced vascu-
lar resistance
Arteriovenous fistula
Paget disease
Beriberi
Table LII. Selected causes of secondary hypertension
Related to 
medications, 
substances, 
and electrolyte 
disturbances
mTOR inhibitors (ciclosporin, tacrolimus)
Erythropoietin
Oral contraceptives (oestrogen, progestin)
Glucocorticosteroids
Mineralocorticoids
Sympathomimetics
MAO inhibitors
Antidepressant drugs (SSRI, tricyclic antidepres-
sants)
Buspirone
Modafinil
Carbamazepine
Methylphenidate
Non-steroidal anti-inflammatory drugs
Vitamin D overdose
Hypercalcaemia
Teophilline
Amphetamine and derivatives (ephedrine,  
pseudoephedrine)
Cocaine
Heroin
Ginseng
Heavy metals
Oncological drugs (anti-VEGF agents, cisplatine, 
carboplatine, paclitaxel, docetaxel,  
5-fluorouracil)
Hypervolaemia
Renal failure
Heart failure
SIADH
Obstructive 
sleep apnoea
Obesity
Adenotonsillar hypertrophy
Anatomical defects of the splanchnocranium
Syndromic  
hypertension
Turner syndrome
Marfan syndrome
Klinefelter syndrome
Down syndrome
Klippel-Trenaunay-Weber syndrome
Feuerstein-Mims syndrome
von Hippel-Lindau disease
von Recklinghausen disease
Klippel-Feil syndrome
Alagille syndrome
Tuberous sclerosis
Ehlers-Danlos syndrome
Monogenic  
hypertension
Liddle syndrome
Apparent mineralocorticoid excess
Pseudohypoaldosteronism type II
MR receptor mutation
Familial hyperaldosteronism type I–IV
17-a-hydroxylase deficiency
Familial glucocorticoid resistance
Brachydactylia with hypertension
CNS — central nervous system; MAO — monoaminooxidase; mTOR — mammalian target of rapamycin; SSRI — selective serotonin reuptake inhibitor; VGEF — vascular endothelial growth factor; SIADH — syndrome 
of inappropriate antidiuretic hormone
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9.14.1. Management of neonatal hypertension
Given the lack of long-term randomized studies 
to evaluate outcomes of antihypertensive therapy 
in neonates, most recommendations are expert 
opinions based on clinical experience. It is not rec-
ommended to initiate treatment in asymptomatic 
neonates with BP values between the 95th and 99th 
percentile. Initiation of drug treatment is justi-
fied when BP values are above the 99th percentile, 
or target organ damage is present with BP val-
ues above the 95th  percentile. The general rule 
of drug treatment in newborns and infants is to 
choose medications depending on the potential 
aetiology of hypertension and the presence of con-
comitant abnormalities, and the treatment should 
be started with as low doses as possible. The safest 
approach is to use short-acting intravenous drugs 
(Tab.  LVII). Oral antihypertensive therapy is re-
served for neonates in a good overall clinical condi-
tion (Tab. LVIII).
Table LIII. Reference systolic blood pressure values (95th percentile) 
in neonates and infants
Age 
95th percentile SBP during the first year 
of life [mm Hg]
Boys Girls
≤ 7 days 96 96
8–30 days 104 104
1 month 104 104
2 months 109 106
3 months 110 108
4 months 110 109
5 months 110 112
6–12 months 110 113
Postconceptional age 95th percentile 99th percentile
44 weeks of gestations
SBP 105 110
DBP 68 73
MAP 80 85
42 weeks of gestation
SBP 98 102
DBP 65 70
MAP 76 81
40 weeks of gestation
SBP 95 100
DBP 65 70
MAP 75 80
38 weeks of gestation
SBP 92 97
DBP 65 70
MAP 74 79
36 weeks of gestation
SBP 87 92
DBP 65 70
MAP 72 71
Table LIV. Blood pressure values (95th and 99th percentile) at 2 weeks of life in neonates born between 26 and 44 weeks of gestation
DBP — diastolic blood pressure; MAP — mean arterial pressure; SBP — systolic blood pressure
Postconceptional age 95th percentile 99th percentile
34 weeks of gestation
SBP 85 90
DBP 55 60
MAP 65 70
32 weeks of gestation
SBP 83 88
DBP 55 60
MAP 62 69
30 weeks of gestation
SBP 80 85
DBP 55 60
MAP 65 68
28 weeks of gestation
SBP 75 80
DBP 50 54
MAP 58 63
26 weeks of gestation
SBP 72 77
DBP 50 56
MAP 57 63
Table LV. Technique of blood pressure measurements in neonates
1.  Measurement using an oscillometric device
2.  1.5 hours after feeding or a medical intervention
3.  Child supine or prone
4.  Selection of an appropriately sized cuff
5.  BP measurement on the right arm
6.  Earlier placement of the cuff and BP measurement  
     after 15 minutes of a quiet rest
7.  BP measurement during sleep or in a quiet awake state
8.  3 properly performed BP measurements 2 minutes apart
BP — blood pressure
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Table LVI. Criteria for the diagnosis of target organ damage in neonates
Target organ damage Diagnostic criteria
Eye fundus Keith-Wagener-Barker grade 3/4 retinopathy
Albuminuria No reference values
cIMT No reference values, technically difficult to evaluate
Features of hypertensive cardiomyopathy and aortopathy:
• Systolic dysfunction without left ventricular enlargement
• Left ventricular hypertrophy
• Indirect evidence of left ventricular diastolic dysfunction — left atrial 
enlargement
• Enlargement of the ascending aorta
• Ejection fraction < 60%
• Shortening fraction < 29%
• Left ventricular mass index > 47.4 ± 6.2 g/m2
• Left atrial dimension > 1.89 ± 0.27 cm
• Ascending aortic dimension > 1.04 ± 0.2 cm
cIMT — common carotid artery intima-media thickness
Table LVII. Intravenous antihypertensive drugs used in neonates
Antihypertensive 
drugs Dosage Comments
Diazoxide 2–5 mg/kg per doseRapid intravenous infusion
Slow infusion is ineffective, may cause acute hypotension
Currently not routinely used for the treatment of hypertension
Enalaprilat
15 ± 5 μg/kg per dose
Repeat q 8–24 hours
Injections every 5–10 minutes
May result in long-term hypotension or acute kidney failure
Use limited due to these adverse effects
Esmolol Infusion: 100–300 μg/kg/min Short-acting drug, continuous intravenous infusion necessary
Hydralazine Infusion: 0.75–5.0 μg/kg/minBolus: 0.15–0.6 μg/kg per dose Frequent tachycardia; boluses given every 4 hours
Labetalol Infusion: 0.25–3.0 μg/kg/hourBolus: 0.2–1.0 μg/kg per dose Contraindications: heart failure, bronchopulmonary dysplasia
Nicardipine Infusion: 1–3 μg/kg/min May result in reflex tachycardia
Sodium  
nitroprusside Infusion: 0.15–10 μg/kg/min Risk of cyanide poisoning if long-term use or renal failure
Table LVIII. Oral antihypertensive drugs used in neonates
Antihypertensive 
drug Dosage Dosing interval Comments
Captopril  < 6 months: 0.01–0.5 mg/kg per dose, maximum 6 mg/kg/day 3 × day
Drug of choice in most neonates. Need to monitor potas-
sium and creatinine level
Clonidine 5–10 μg/kg/day,  maximum 25 μg/kg/day 2–3 × day
Side effects: dry mouth, somnolence, and constipation  
Rebound hypertension if stopped abruptly
Hydralazine 0.25–1.0 mg/kg per dose,  maximum 7.5 mg/kg/day 3–4 × day Tachycardia and fluid retention are frequent adverse effects
Isradipine 0.05–0.15 mg/kg per dose,  maximum 0.8 mg/kg/day 4 × day Effective in acute and chronic hypertension
Amlodipine 0.1–0.3 mg/kg per dose,  maximum 0.6 mg/kg/day 2 × day Hypotension less frequent than with isradipine
Minoxidil 0.1–0.2 mg/kg per dose 2–3 × day Most potent oral vasodilator. Effective in resistant  hypertension
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Table LVIII. Oral antihypertensive drugs used in neonates (continued)
Antihypertensive drug Dosage Dosing interval Comments
Propranolol 0.5–1.0 mg/kg per dose 3 × day
Maximum dose depends on heart rate
If bradycardia is not present, the dose may be increased to  
8–10 mg/kg/day
Contraindicated in bronchopulmonary dysplasia
Labetalol 1.0 mg/kg/dose,  maximum 10 mg/kg/day 2–3 × day
Contraindicated in bronchopulmonary dysplasia
Need to monitor heart rate
Spironolactone 0.5–1.5 mg/kg per dose 2 × day Results in potassium retention — need to monitor electrolytesFull effect seen after several days
Hydrochlorothiazide 1–3 mg/kg per dose 4 × day Need to monitor electrolytes
Chlorothiazide 5–15 mg/kg/dose 2 × day Need to monitor electrolytes
9.14.2. Early diagnosis of hypertension during 
postdischarge care for children born below 
34 weeks of gestation
Prematurity and low birth weight are risk factors 
for the development of hypertension. It has been 
estimated that at 3 years of age, hypertension is diag-
nosed in 7.3% of children born prematurely. The risk 
of hypertension increases with age and is particularly 
high in children born at ≤ 33 weeks of gestation.
During specialist postdischarge care for children 
born prematurely in whom BP is measured, the ap-
proach presented above should be followed, using 
respective BP reference values (see: Neonatal hyper-
tension). 
9.14.2.1. Screening for hypertension during 
postdischarge care for children born prematurely  
(at ≤ 33 weeks of gestation) 
The present guidelines have adopted the approach to 
postdischarge care for children born prematurely rec-
ommended by the Polish Neonatal Society in 2018 
and by the Low Birth Weight and Nephron Number 
Working Group in 2017.
Children with the diagnosis of hypertension be-
fore discharge from a neonatal unit should be con-
sulted and enlisted for specialist care in a paediatric 
hypertension unit already before hospital discharge. 
Further diagnostic and therapeutic management 
should be based on the current paediatric PTNT, 
IP-CZD and ESC recommendations.
Children with accompanying kidney and urinary 
tract pathology should be enlisted for specialist care 
in a paediatric nephrology, hypertension, and urol-
ogy unit. This will allow early planning of both the 
treatment of the urinary tract pathology and nephro-
protective treatment. 
In children in whom elevated BP values have not 
been identified before discharge from the neonatal 
unit should have BP measured at each visit. In pa-
tients below 3 years of age, automatic measurements 
on the right arm are recommended as the primary 
BP measurement method. If elevated BP values are 
identified, this should be confirmed by the ausculta-
tory method. The diagnosis of hypertension is an in-
dication for referral to a paediatric hypertension unit.
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